Clinical and internal medicine Books

Book SynopsisPalliative Medicine is the professional medical practice of prevention and relief of suffering and the support of the best possible quality of life for patients and their families, regardless of the stage of the disease or the need for other therapies. This book uses a multidisciplinary approach to content and patient treatment.Trade Review“This is an excellent book that addresses a crucial aspect of radiotherapy in a way that I have not seen before. It is concise and easy to digest, but also packed with information that will help guide healthcare professionals in their practice. It would be useful for palliative care clinicians and medical oncologists, but is of particular use as a reference text to radiation oncologists and their trainees.” (European Journal of Palliative Care, 21 April 2014)Table of ContentsContributor list xv Foreword xix Part 1: General principles of radiation oncology 1 1 A brief history of palliative radiation oncology 3 Joshua Jones Introduction 3 The early years 3 Fractionation 6 Advances in radiotherapy technique: the 1950s and 1960s 7 Fractionation revisited: explicit palliation 10 Stereotactic radiotherapy 11 Prognostication and tailoring palliative radiotherapy to anticipated survival 11 Conclusion 12 References 13 2 The radiobiology of palliative radiation oncology 15 Candice A. Johnstone Introduction 15 Radiation effect on cells 15 Cell cycle characteristics 18 Interaction of cell cycle and radiotherapy fractionation 18 Radiotherapy fractionation characteristics 19 Conclusion 20 References 20 3 The physics of radiation oncology 22 Shaun Baggarley Jiade J. Lu Introduction 22 The development of radiation therapy technology 24 Process of radiation therapy 27 Special considerations in developing countries 28 Conclusion 29 References 29 4 Curative intent versus palliative intent radiation oncology 31 Vassilios Vassiliou Haris Charalambous Introduction 31 The determination of cure plus palliation intent versus pure palliative intent 33 Clinical diagnoses 35 Special considerations in developing countries 38 Conclusion 39 References 39 5 Side effects of palliative radiotherapy 43 Alysa Fairchild Introduction 43 Issues with interpreting palliative radiotherapy toxicity data 44 Acute side effects 45 Late side effects 50 Additive toxicity 53 Clinical advice 53 New technologies 55 Challenges in developing countries 55 Conclusion 56 References 56 Part 2: General principles of palliation and symptom control 61 6 A history of hospice and palliative medicine 63 Michelle Winslow Marcia Meldrum Introduction 63 Before the modern movement 63 St. Christopher’s and the modern hospice 64 Palliative care in the United States 66 Global development of hospice and palliative care 68 Continuing challenges 69 References 69 7 Radiation therapy and hospice care 72 Charles F. von Gunten Frank D. Ferris and Arno J. Mundt Introduction 72 Hospice care around the world 72 Hospice care in the United States 73 Palliative radiation and hospice 77 Conclusion 79 References 79 8 The current status of palliative care and radiotherapy 81 Thomas Smith Susannah Batko-Yovino What is palliative care? 81 Who can benefit from palliative care? 81 What are the goals of palliative care and what features of a palliative care program help to accomplish these goals? 83 What is the evidence regarding the benefi ts and risks of palliative care? When should palliative care be introduced to a patient? 84 Are there standards for palliative care? If so what are the defining measures? 88 How does palliative care fi t in with radiation oncology? 90 References 92 9 Palliative care in low and middle income countries: A focus on sub-Saharan Africa 95 Henry Ddungu Elizabeth A. Barnes Introduction 95 The need for palliative care 95 Radiotherapy 96 Specific clinical indications for palliative radiotherapy in Africa 97 Challenges of palliative care delivery 98 Addressing challenges to adequate palliative care 98 Palliative care research 100 Delivery of palliative care 101 Conclusion 102 References 102 10 Pain management 105 Erin McMenamin Introduction 105 Pain assessment 105 Analgesia ladder 106 Primary pharmacologic interventions 107 Adjuvant medications 108 End-of-life considerations 109 Conclusion 109 References 110 Part 3: Locally advanced or locally recurrent diseases 113 11 Primary tumors of the central nervous system 115 Caroline Chung Eric L. Chang Introduction 115 Radiotherapy 116 Side-effect risks 120 Radiotherapy limitations 120 Adjuvant treatment modalities 121 Promise of newer technologies 121 Special considerations in developing countries 122 Conclusion 122 References 122 12 The role of palliative care in head and neck cancer 126 Albert Tiong June Corry Introduction 126 Current management of head and neck squamous cell carcinomas 126 Patient selection for palliative treatment 127 Use of palliative radiotherapy in head and neck squamous cell carcinomas 130 Recurrent disease 134 The promise of emerging technologies 135 Chemotherapy in palliative head and neck squamous cell carcinomas 135 Non-squamous cell carcinomas histologies 136 Specific issues in palliation of head and neck squamous cell carcinomas 137 Special considerations in developing countries 138 Conclusion 138 References 139 13 The role of palliative radiotherapy in breast cancer 145 Ian H. Kunkler Introduction 145 Rates of palliative loco-regional radiotherapy 148 Biologic considerations 148 Definitions clinical features and multi-disciplinary approach 148 Clinical scenarios 150 Symptom control 153 Palliative loco-regional radiotherapy for oligometastatic disease 154 Radiotherapy dosing schedules 154 Radiotherapy technique and the promise of newer technology 156 Special considerations in developing countries 158 Follow up 158 Conclusion 159 References 159 14 Palliative radiotherapy in advanced lung cancer 163 George Rodrigues Benjamin Movsas Introduction 163 Radiotherapy treatment 165 The impact of emerging technologies 169 Important circumstances 171 Special considerations in developing countries 173 Conclusion 173 References 174 15 Palliative radiotherapy for gastrointestinal and colorectal cancer 177 Robert Glynne-Jones Mark Harrison Introduction 177 Treatment of dysphagia 178 Gastric cancer 180 Palliation of biliary obstruction 181 Nodes at origin of the superior mesenteric artery 181 High dose rate brachytherapy 182 Locally advanced/recurrent rectal cancer 182 Re-irradiation 184 Anal cancer 184 The promise of highly conformal therapy 184 Special considerations in developing countries 184 Conclusion 185 References 185 16 Genitourinary malignancies 188 Gillian M. Duchesne Introduction 188 Incidence and etiology 188 Clinical behavior 190 Bladder cancer 190 Prostate cancer 190 Renal cancer 190 Palliative radiotherapy and other approaches for management of primary disease 192 Specific management of metastatic disease in urologic malignancies 194 The promise of highly conformal therapy 196 Special considerations in developing countries 197 Conclusion 197 References 197 17 Palliative radiotherapy in locally advanced and locally recurrent gynecologic cancer 199 Firuza Patel Introduction 199 Patterns of loco-regional failures for gynecologic cancers 200 Management 201 Treatment of recurrent carcinoma of the cervix 206 Recurrence after defi nitive radiation 206 Recurrence after defi nitive surgery 207 The promise of newer technologies 207 Special considerations in developing countries 207 Conclusion 208 References 209 18 Hematologic malignancies and associated conditions 210 David D. Howell Introduction 210 Diagnoses 210 Specific clinical circumstances 213 Locally advanced and recurrent disease 216 Future directions 216 Special considerations in developing countries 217 Conclusion 217 References 217 19 Pediatric palliative radiation oncology 220 Tamara Vern-Gross Introduction 220 Delivery of radiation treatment 221 Differences between pediatric and adult populations 222 Background 222 Clinical indications for palliative radiotherapy 224 Caring for the pediatric patient 232 Barriers to the use of palliative radiotherapy 233 Special considerations in developing countries 233 Conclusion 234 References 234 Part 4: Metastatic disease 239 20 Bone metastases 241 Yvette van der Linden Dirk Rades Introduction 241 Clinical implications and treatment modalities 241 Clinical symptoms 242 Technical considerations 250 Prognosis and choice for treatment 250 Proactive approach 251 Special considerations in developing countries 251 Conclusion 251 References 253 21 Spinal cord compression 257 Ernesto Maranzano Fabio Trippa Introduction 257 Treatment 259 Promise of newer technologies 264 Re-irradiation 265 Special considerations in developing countries 265 Conclusion 266 References 267 22 Brain metastases 270 May Tsao Introduction 270 Radiotherapy treatment 271 Radiotherapy limitations 277 Promise of newer technologies and areas of ongoing research 277 International patterns of care and special considerations in developing countries 278 Conclusion 278 References 279 23 Liver metastases 283 Sean Bydder Introduction 283 Radiotherapy treatment 284 Whole-liver radiation therapy 286 Conformal radiation therapy 288 Brachytherapy 289 Selective internal radiation therapy 289 Surgery for liver metastases 290 Radiofrequency ablation 290 Promising new radiotherapy techniques 290 Practice variation among different countries 293 Conclusion 294 Acknowledgments 294 References 294 24 Palliative radiotherapy for malignant neuropathic pain adrenal choroidal and skin metastases 299 Daniel E. Roos Aaron H. Wolfson Malignant neuropathic pain 299 Adrenal metastases 302 Choroidal metastases 308 Skin metastases (A.H. Wolfson) 312 Conclusion 314 References 314 Part 5: Integration of radiation oncology and palliative care 317 25 Design challenges in palliative radiation oncology clinical trials 319 Deborah Watkins Bruner Lawrence B. Berk Introduction 319 Challenges with the validation of palliative metrics 319 Evolution of palliative care clinical trials: the Radiation Therapy Oncology Group experience 320 International research efforts 325 Conclusion 326 References 326 26 Radiation oncology cost-effectiveness 329 Andre Konski Introduction 329 Cost-effectiveness 330 Newer technologies 332 Conclusion 333 References 333 27 Quality measures and palliative radiotherapy 335 James A. Hayman Rinaa S. Punglia and Anushree M. Vichare Introduction 335 Quality measures: characteristics 336 Developing quality measures 338 Desirable attributes of quality measures 340 Uses of quality measures 340 Current uses of quality measures in radiation oncology 341 International quality measures in radiation oncology 342 Conclusion 343 References 344 28 Use of technologically advanced radiation oncology techniques for palliative patients 347 Simon S. Lo Bin S. Teh Samuel T. Chao Arjun Sahgal Nina A. Mayr and Eric L. Chang Introduction 347 Overview of technologically advanced radiotherapy techniques 347 Clinical applications reported in the literature 349 Brain metastasis 349 Stereotactic radiosurgery 349 Scalp-sparing whole brain radiation therapy 351 Hippocampus-sparing whole brain radiation therapy 351 Stereotactic radiation therapy 351 Spinal metastasis 352 Spinal cord compression 352 Bone metastasis 355 Adrenal metastasis 355 Toxicities associated with palliative radiotherapy using advanced technologies 356 Conclusion 357 References 357 Index 361

Read more less

Book SynopsisProvides expert, state-of-the-art insight into the current progress of viral and non-viral gene therapy Translational medicine has opened the gateway to the era of personalized or precision medicine. No longer a one-size-fits-all approach, the treatment of cancer is now based on an understanding of underlying biologic mechanisms and is increasingly being tailored to the molecular specificity of a tumor. This book provides a comprehensive overview of the pertinent molecular discoveries in the cancer field and explains how these are being used for gene-based cancer therapies. Designed as a volume in the Translational Oncology book series, Cancer Gene Therapy by Viral and Non-viral Vectors deals with the practice of gene-therapy, with reference to vectors for gene expression and gene transfer, as well as viral therapy. It covers the history and current and future applications of gene transfer in cancer, and provides expert insight on the progress of virTable of ContentsList of Contributors, vii Series Foreword, ix Preface, xi Part I Delivery Systems 1 Translational Cancer Research: Gene Therapy by Viral and Non-viral Vectors, 3 Vincenzo Cerullo, Kilian Guse, Markus Vähä-Koskela, and Akseli Hemminki 2 Retroviruses for Cancer Therapy, 21 Jiehua Zhou, Yue Ding, John C. Burnett, and John Rossi 3 DNA Plasmids for Non-viral Gene Therapy of Cancer, 39 Amer M. Najjar, Judy S.E. Moyes, and Laurence J.N. Cooper 4 Cancer Therapy with RNAi Delivered by Non-viral Membrane/Core Nanoparticles, 61 Andrew B. Satterlee and Leaf Huang Part II Targeted Expression 5 Cancer Gene Therapy by Tissue-specific and Cancer-targeting Promoters, 81 Jennifer L. Hsu, Longfei Huo, Chia-Wei Li, Yi-Hsin Hsu, Yan Wang, and Mien-Chie Hung 6 MicroRNAs as Drugs and Drug Targets in Cancer, 97 Hui Ling and George A. Calin Part III Principles of Clinical Trials in Gene Therapy 7 Regulatory Issues for Manufacturers of Viral Vectors and Vector-transduced Cells for Phase I/II Trials, 115 Adrian P. Gee and Zhuyong Mei 8 US Regulations Governing Clinical Trials in Gene Therapy, 131 Bambi Grilley 9 Remaining Obstacles to the Success of Cancer Gene Therapy, 151 Malcolm K. Brenner Index, 157

Read more less

Book Synopsis

Read more less

Book SynopsisAn integrated presentation of the basic science and clinical applications of anticancer agents Aimed at both undergraduate and postgraduate readers, this unique text provides readers with a fully-integrated presentation of all aspects of the science of anticancer drugs, including their chemistry, pharmacology, and clinical applications. After heart disease, cancer is the number one killer worldwide, and the tumor microenvironment is forever changing, creating an ever-greater demand for safer, more effective anticancer agents. In response to that demand, the $100 billion cancer drug market continues to grow, with our increased understanding of cancer leading to new drugs being used clinically almost every year. Anticancer Therapeutics is divided into three sections. Section 1 is an introduction to cancer and therapeutics, and covers the etiology and cellular and molecular basis of cancer. In Section 2, the authors focus on the anticancer agents theTable of ContentsPreface xi Section 1: Introduction 1 1.1 The Global Burden of Cancer 3 References 11 1.2 Cancer Staging and Classification 13 1.2.1 Benign Tumour (or neoplasm) 13 1.2.2 Malignant Tumour (or cancer) 14 1.2.3 Tumour Nomenclature and Classification 14 1.2.4 Cellular Differentiation and Tumour Grade 21 1.2.5 Tumour Invasion and Metastasis 24 1.2.6 Clinical Staging of Cancer 26 References 36 1.3 Cellular and Molecular Basis of Cancer 39 1.3.1 Oncogenes 40 1.3.2 Tumour Suppressor Genes 45 1.3.3 Role of Epigenetics and Gene Promoter Regulation in Tumourigenesis 49 1.3.4 Multistage Tumourigenesis 53 1.3.5 Oncogene Addiction 54 1.3.6 Hallmarks of Cancer 55 1.3.7 Principles of Cancer Treatment 73 References 77 Section 2: The Anticancer Agents 81 2.1 Agents Which Act Directly on DNA 83 2.1.1 Nitrogen Mustards and Nitrosoureas 83 References 96 2.1.2 Temozolomide 98 References 106 2.1.3 Platinum]containing Agents 108 References 118 2.1.4 Gemcitabine 120 References 128 2.1.5 Camptothecin and Its Analogues 128 References 139 2.1.6 Podophyllotoxins 141 References 150 2.1.7 Anthracyclines 151 References 160 2.1.8 Epigenetic Targeting Agents 162 References 177 2.2 Antimetabolites 181 2.2.1 Cytarabine 181 References 183 2.2.2 Methotrexate 184 References 195 2.2.3 5]Fluorouracil 196 References 205 2.2.4 6]Mercaptopurine 206 References 210 2.3 Antimicrotubule Agents 211 2.3.1 Taxanes 211 References 224 2.3.2 Vinca Alkaloids 225 References 231 2.4 Anti]hormonal Agents 233 2.4.1 Bicalutamide 233 References 239 2.4.2 Tamoxifen 240 References 247 2.4.3 Anastrozole 248 References 254 2.5 Kinase Inhibitors 257 2.5.1 Discovery 257 2.5.2 Synthesis 262 2.5.3 Mode of Action 267 2.5.4 Mechanism of Resistance 268 2.5.5 Adverse Drug Reactions 268 References 271 Section 3: The Cancers 275 3.1 Breast Cancer 277 Key points 277 3.1.1 Epidemiology 277 3.1.2 Presentation 279 3.1.3 Diagnosis 282 3.1.4 Staging 283 3.1.5 Treatments 285 References 289 3.2 Colorectal Cancer 293 Key points 293 3.2.1 Epidemiology 293 3.2.2 Presentation 294 3.2.3 Diagnosis 296 3.2.4 Staging 298 3.2.5 Treatments 299 References 303 3.3 Leukaemia 307 Key points 307 3.3.1 Epidemiology 307 3.3.2 Presentation 310 3.3.3 Diagnosis 311 3.3.4 Staging 313 3.3.5 Treatments 314 References 319 3.4 Lung Cancer 323 Key points 323 3.4.1 Epidemiology 323 3.4.2 Presentation 327 3.4.3 Diagnosis 327 3.4.4 Staging 330 3.4.5 Treatments 330 References 337 3.5 Oesophageal Cancer 339 Key points 339 3.5.1 Epidemiology 339 3.5.2 Presentation 340 3.5.3 Diagnosis 341 3.5.4 Staging 344 3.5.5 Treatments 346 References 350 3.6 Ovarian Cancer 353 Key points 353 3.6.1 Epidemiology 353 3.6.2 Presentation 354 3.6.3 Diagnosis 356 3.6.4 Staging 357 3.6.5 Treatments 357 References 363 3.7 Pancreatic Cancer 367 Key points 367 3.7.1 Epidemiology 367 3.7.2 Presentation 368 3.7.3 Diagnosis 370 3.7.4 Staging 371 3.7.5 Treatments 373 References 375 3.8 Prostate Cancer 379 Key points 379 3.8.1 Epidemiology 379 3.8.2 Presentation 381 3.8.3 Diagnosis 382 3.8.4 Staging 384 3.8.5 Treatments 387 References 391 3.9 Skin Cancers 393 Key points 393 3.9.1 Epidemiology 393 3.9.2 Presentation 394 3.9.3 Diagnosis 395 3.9.4 Staging 396 3.9.5 Treatments 399 References 403 3.10 Testicular Cancer 405 Key points 405 3.10.1 Epidemiology 405 3.10.2 Presentation 407 3.10.3 Diagnosis 407 3.10.4 Staging 409 3.10.5 Treatments 409 References 414 Index 417

Read more less

Book SynopsisThe Retinoids: Biology, Biochemistry, and Disease provides an overview and synthesis of the retinoid molecules, from basic biology to mechanisms of diseases and therapy. Divided into five sections, the book covers retinoic acid signaling from biochemical, genetic, developmental, and clinical perspectives.Table of ContentsContributors ix Preface xiii Part I: Vitamin A metabolic and enzymatic pathways 1 1 Vitamin a Metabolism, Storage and Tissue Delivery Mechanisms 3William S. Blaner and Yang Li 2 Assimilation and Conversion of Dietary Vitamin a into Bioactive Retinoids 35Earl H. Harrison and Carlo dela Senã’s 3 Intracellular Storage and Metabolic Activation of Retinoids: Lipid Droplets 57Joseph L. Napoli and Charles R. Krois 4 Evolution of the Retinoic Acid Signaling Pathway 75Vincent Laudet, Elisabeth Zieger, and Michael Schubert Part II: Biochemistry and cellular biology of retinoic acid signaling 91 5 Control of Gene Expression by Nuclear Retinoic Acid Receptors: Post-Translational And Epigenetic Regulatory Mechanisms 93Marilyn Carrier and Cécile Rochette-Egly 6 Retinoic Acid Receptor Coregulators in Epigenetic Regulation of Target Genes 117Li-Na Wei 7 Retinoid Receptors: Protein Structure, Dna Recognition and Structure–Function Relationships 131William Bourguet and Dino Moras 8 How the RAR–RXR Heterodimer Recognizes the Genome 151Sylvia Urban, Tao Ye, and Irwin Davidson 9 Retinoid Receptor-Selective Modulators: Chemistry, 3D Structures and Systems Biology 165Marco-Antonio Mendoza-Parra, William Bourguet, Angel R. de Lera, and Hinrich Gronemeyer 10 Use of Retinoid Receptor Ligands to Identify Other Nuclear Receptor Ligands: Retinoid-Related Molecules are Ligands for the Small Heterodimer Partner (SHP) “Orphan” Receptor 193Marcia I. Dawson and Zebin Xia 11 The Dual Transcriptional Activity of Retinoic Acid 273Noa Noy 12 Retinoids, epigenetic changes during stem cell differentiation, and cell lineage choice 291Lorraine J. Gudas Part III: RETINOIC ACID SIGNALING IN DEVELOPMENT 307 13 Retinoic Acid Signaling and Central Nervous System Development 309Malcolm Maden 14 The Role of Retinoic Acid in Limb Development 339Gregg Duester 15 Retinoic Acid Signaling and Heart Development 353Stéphane Zaffran and Karen Niederreither 16 Retinoic Acid in the Developing Lung and Other Foregut Derivatives 371Wellington V. Cardoso and Felicia Chen 17 Retinoic Acid and the Control of Meiotic Initiation 383Josephine Bowles and Peter Koopman Part IV: RETINOIDS AND PHYSIOLOGICAL FUNCTIONS 401 18 Retinoids and the Visual Cycle: New Actors for an “OLD” Function 403Darwin Babino and Johannes von Lintig 19 Retinoid Signaling in the Central Nervous System 421Peter McCaffery and Wojciech Krężel 20 Retinoid Turnover and Catabolism: Influences of Diet and Inflammation 449A. Catharine Ross and Reza Zolfaghari 21 Retinoids and the Immune System 465J. Rodrigo Mora and Makoto Iwata 22 Retinoic Acid Receptor Signaling in Post-Natal Male Germ Cell Differentiation 485Manuel Mark and Norbert B. Ghyselinck Part V: RETINOIDS, DISEASE AND THERAPY 505 23 Epidemiology and Prevention of Vitamin a Deficiency Disorders 507Keith P. West, Jr. 24 Retinoid Pathway Gene Mutations and the Pathophysiology Of Related Visual Diseases 529Yaroslav Tsybovsky and Krzysztof Palczewski 25 Retinoic Acid in Acute Myeloid Leukemias 543Hugues de Thé and Pierre Fenaux 26 Advances in the Use of Retinoids in Cancer Therapy and Prevention 557Michael J. Spinella, Sarah J. Freemantle, and Ethan Dmitrovsky Index 575

Read more less

Book SynopsisThe emerging understanding of age-related neurological disorders suggests that notions of a single causal gene/toxin being responsible is likely incorrect. Neurological disorders probably arise due to a unique intersection of multiple genetic and toxic factors, combined with additional contributions of age, stage of development, immune system actions, and more. This perspective leads to the view that rather than reflecting only one pathway to end-state disease, each is a spectrum disorder, and every individual case is therefore unique. Neural Dynamics of Neurological Disease argues for a fundamental rethinking of what we think we know about neurological disorders, how they arise and progress, and, crucially, what might be done to cure them. It first introduces the concept of neural dynamics of neurological disease, then examines various diseases and gives examples of the interplay of elements such as neural systems, cell types, and biochemical pathways that can contribute to diseaseTable of ContentsPreface xv Acknowledgments xxi Part I The Dynamics of Neurological Disease 1 1 The Dynamics of Neurological Disease: Current Views and Key Issues 3 1.1 Introduction 4 1.2 The Complexity of Human Neurological Diseases 4 1.3 The Nervous System as an Archetypical Complex System 9 1.4 CNS Signaling Failures: Implications for Neurological Disease 14 1.5 History and Key Characteristics of the Age-Dependent Neurological Diseases 14 1.6 The Fractal Nature of Complexity in the CNS 16 Endnotes 17 2 Clinical and Economic Features of Age-Related Neurological Diseases 19 2.1 Introduction 19 2.2 Parkinson’s Disease 19 2.3 Amyotrophic Lateral Sclerosis 29 2.4 Alzheimer’s Disease 40 2.5 Summary of the Data on the Progressive, Age-Related Neurological Diseases 47 2.6 Neural Loci and Mechanisms of Action 48 Endnote 49 3 Spectrums of Neurological Disease, Clusters, and Ubiquity 51 3.1 Introduction 51 3.2 Spectrums of Neurological Disease 51 3.3 The Dimension of the Problem when Assessing Potential Causal Factors in Neurological Diseases 54 3.4 Neurological Disease Clusters 57 3.5 Ubiquity 60 3.6 Nested Complex Systems: Proximal versus Distal Events as They May Relate to Neurological Diseases 60 3.7 The Path to “Curing” Neurological Diseases 63 4 Complexity, Cascading Failures, and Neurological Diseases 67 4.1 Introduction 67 4.2 Introduction to Complexity Theory and Complex Systems 67 4.3 Computer Programs and Computer Crashes 69 4.4 Biosemiosis in the CNS (Part 1) 70 4.5 Complexity in the CNS and the Impact of Genetic and Environmental Insults 73 4.6 Tipping Points and Time Lines of Disease Progression 77 5 Genetic Determinants of Neurological Disease 79 5.1 Introduction 80 5.2 Causality versus Coincidence 80 5.3 Actions of Mutant Genes in Neurological Disease 82 5.4 Genetic Mutations Linked to Parkinson’s Disease 84 5.5 Genetic Mutations Linked to ALS 86 5.6 Genetic Mutations Linked to Alzheimer’s Disease 92 5.7 Genes and Neurological Disease: Some General Considerations 94 6 Environmental Determinants of Neurological Disease and Gene–Toxin Interactions 97 6.1 Introduction 98 6.2 Toxins and Neurological Diseases 98 6.3 Aluminum and Neurological Disease 101 6.4 Single- vs. Multiple-Hit Models of Neurological Disease: Gene–Toxin Interactions 114 6.5 Genetic Susceptibility Factors 117 6.6 Biosemiosis (Part 2) 123 6.7 Gene–Toxin Interactions and Cascading Failures 124 6.8 Genes and Toxins in Neurological Disease: Penultimate Thoughts 124 6.9 And, Finally, the Microbiome 125 Endnote 125 7 The Mystery and Lessons of ALS-PDC 127 7.1 Introduction 127 7.2 Neurological Disease Clusters and ALS-PDC 128 7.3 History and Features of ALS-PDC 129 7.4 Cycad and ALS-PDC 135 7.5 Amino Acid Toxins in Cycad and ALS-PDC 140 7.6 Non-Amino Acid Toxins Linked to ALS-PDC 143 7.7 Aluminum and Ionic Etiologies for ALS-PDC 147 7.8 Still Other Molecules Causal to ALS-PDC 148 7.9 What is the Current View on the Importance of ALS-PDC? 148 7.10 Complexity of Neurological Diseases as Viewed from Guam 151 Endnote 151 Part II Age and Time Lines of Neurological Disease 153 8 Neurological Disease Models and their Discontents: Validity, Replicability, and the Decline Effect 155 8.1 Introduction 155 8.2 Modeling Human Neurological Diseases: Possibilities and Pitfalls 156 8.3 Considerations Regarding Model Systems 158 8.4 Model Systems and their Discontents 159 8.5 Is There an Ideal Model for Studying Neurological Diseases? General Considerations 168 8.6 Specific Considerations for Ideal Model-System Approaches in ALS 170 8.7 Alternative Views of Neurological Disease and Model-Systems Approaches: Multiple-Hit Etiologies 172 9 The Progression and the Time Line of Neurological Disease 175 9.1 Introduction 175 9.2 Creating Disease Time Lines: The Framingham Study 176 9.3 Time Lines of Neurological Disease 176 9.4 Back to a Multiple-Hit Disease Consideration 180 9.5 Haecceity and Quiddity in Context to Biosemiosis and Multiple Hits 181 9.6 Some Final Thoughts on Time Lines of Neurological Disease: Differentiation and Neurogenesis 182 Endnote 183 10 Development, Aging, and Neurological Disease 185 10.1 Introduction 185 10.2 The Fetal Basis of Adult Disease Hypothesis 186 10.3 ASD as a Developmental Neurological Disorder 188 10.4 Toxins and Developmental CNS Disorders 193 10.5 Developmental versus Mature CNS Disorders 193 Endnotes 194 Part III Interactions and Synergies in Neurological Disease 195 11 CNS–Immune System Interactions and Autoimmunity 197 11.1 Introduction 198 11.2 Immunity and the CNS, an Introduction to a Complex Topic 198 11.3 CNS–Immune System Interactions: More Detailed Considerations 202 11.4 Autoimmunity 205 11.5 Immune System Signaling Errors and Autoimmunity in ASD and Other Neurological Disorders 208 11.6 Laterality and Autoimmunity in Neurological Diseases 212 11.7 Other System Disorders in Neurological Diseases: More Evidence for Autoimmunity? 215 11.8 Are There Infectious Disease Links to Neurological Diseases? 215 12 The Impact of Synergy of Factors in Neurological Disease 219 12.1 Introduction 219 12.2 Synergistic and Additive Effects in General and as Applied to CNS Diseases 219 12.3 Gene–Environment (Toxin) Interactions in Non-neuronal Systems 221 12.4 Gene–Environment (Toxin) Interactions in Neurological Disease 224 12.5 Levels of Complexity in Gene–Toxin Interactions: Implications for Current and Future Therapeutics 226 Part IV Transition and Politics in Neurological Disease 229 13 The Current Status of Neurological Disease Treatments 231 13.1 Introduction 231 13.2 Current Therapeutic Approaches to Treating Neurological Diseases 232 13.3 Summary 242 Endnote 243 14 The Future of Translational Research in Neurological Disease 245 14.1 Introduction 245 14.2 Comparing Traumatic Brain Injury to Neurological Diseases 246 14.3 ALS and Polio: Comparing the Nature of Neural Degeneration and Progression in the Two Diseases 249 14.4 Neurological Diseases as Spectrum Disorders: Implications for Therapy 252 14.5 Cystic Fibrosis and Gene Therapy 254 14.6 Restoring CNS Function: What is the Bottom Line? 255 14.7 Biosemiosis (Part 3) and True Narrative Representations 255 15 Defining the Limits for Neurological Disease Treatments 259 15.1 Introduction 259 15.2 The Complexity of the Human CNS versus One View of the Philosophy of Science 260 15.3 Examples of Unique Individuality: From Pilgrimages to Nature 261 15.4 Therapeutic Windows for the Treatment of Neurological Diseases 266 Endnotes 270 16 The Politics and Economics of Neurological Disease 271 16.1 Introduction 271 16.2 The Problems with Single-Hit Models of Neurological Disease 272 16.3 Summarizing the Main Themes by Chapter 274 16.4 Can the Amount of Money Spent Change these Outcomes for Neurological Disease Treatment? 276 16.5 General Considerations for the Future of Neurological Disease Research 280 16.6 The Advent of Modern Dentistry and Dental Prophylaxis 284 16.7 Addressing Neurological Diseases at the Individual and Population Levels 286 Endnotes 290 Glossary 291 References 301 Index 355

Read more less

Book SynopsisUsing a case-based approach, Colorectal Surgery: Clinical Care and Management providespractical, clinical and expert guidance to illustrate the best care and clinical management of patients requiring colorectal surgery for colorectal disease. Real-life cases illustrate the entire syllabus of GI/colorectal surgery, being specially selected to highlight topical or controversial aspects of colorectal care. Cases have a consistent approach throughout and as well as outlining the actual management of each individual case, also offer an honest appraisal of the chosen management route, its successes and areas that could have been managed differently. Pedagogic features such as learning and decision points boxes aid rapid understanding/learning, enabling the reader to improve their patient management. In full colour and containing over 100 outstanding clinical photos and slides to support the cases, each section also covers recent developments/ landmark papers/ scoring systemsTable of ContentsList of Contributors ix Foreword xiii Section A: Colorectal cancer 1 Bruce George 1 A screen-detected colonic conundrum 25 Ami Mishra 2 Serrated Pathways 28 Sujata Biswas, Lai Mun Wang & Simon Leedham 3 Large tubulovillous adenoma of the rectum treated by TEM 32 Richard Tilson, Shazad Ashraf & Christopher Cunningham 4 To stent or not to stent? 36 Jonathan Randall 5 Advanced rectal cancer: Brazil or Japan? 40 Oliver Jones 6 Marginal decisions 45 Oliver Jones 7 Locally advanced rectal cancer invading prostate 48 Richard Guy, Roel Hompes & Rebecca Kraus 8 Low rectal cancer and synchronous polyps 52 Richard Guy 9 Liver or rectum first? 56 Nicolas Buchs, Frederic Ris & Christian Toso 10 Beware bad livers! 59 Kate Williamson 11 Anastomotic recurrence? 62 Bruce George 12 Challenging warts 65 Emma Bracey & Bruce George 13 An unusual right iliac fossa mass 68 Bruce George Section B: Inflammatory bowel disease 73 Bruce George 14 A problem teenager 91 Astor Rodrigues 15 Recurrent Crohn’s disease with intraabdominal abscess: when to operate? 95 Bruce George & Mohamed Abdelrahman 16 Very extensive small bowel stricturing disease 98 Myles Fleming & Neil Mortensen 17 Long-standing Crohn’s colitis and enterocutaneous fistula 103 Richard Lovegrove 18 Crohn’s colitis 109 Bruce George & Marc Marti-Gallostra 19 Fistulating anal Crohn’s disease: conservative management 112 Silvia Silvans & Bruce George 20 Tail end carnage 116 Bruce George 21 Acute severe colitis 120 Bruce George 22 Snare or pouch? The problem of dysplasia in ulcerative colitis 123 Gareth Horgan & James East 23 Anal fistula and ulcerative colitis 128 Richard Guy 24 Poor pouch function 131 Bruce George 25 Low rectal cancer in a patient with ulcerative colitis: late reconstruction with continent Kockileostomy 135 Par Myrelid & Richard Lovegrove Section C: Pelvic floor disorders 141 Oliver Jones 26 Constrictions of prolapse surgery 167 Richard Guy 27 Elderly prolapse dilemma 170 Koen van Dongen 28 Chasing incontinence 173 Oliver Jones 29 Sphincter disruption 177 Kim Gorissen 30 Stimulating complications 181 Kim Gorissen & Ian Lindsey 31 Crohn’s evacuation trouble 184 Heman Joshi 32 Disabling anal pain 187 Martijn Gosselink & Ian Lindsey Section D: Proctology 191 Richard Guy 33 Hemorrhoids and HIV 217 Richard Guy 34 Refractory fissure 220 Richard Guy 35 Hirschsprung’s fistula 223 Richard Guy 36 Complex fistula in a young woman 227 Martijn Gosselink & Richard Guy 37 Recurrent rectovaginal fistula 232 Bruce George 38 Adolescent cleft trouble 236 Richard Guy 39 Extreme itch 239 Luana Franceschilli Section E: Emergency colorectal surgery 243 Richard Guy 40 Occupational blast disaster 263 Richard Guy 41 Wash and go? 266 Bruce George 42 Absolute constipation 269 Richard Guy 43 Multiply ischemic parts 273 Richard Guy 44 Seriously obscure bleeding 277 Alistair Myers 45 Complicated twist 280 Richard Guy 46 Obscure postoperative obstruction 284 Richard Guy 47 Gynecological disaster 289 Richard Guy 48 Pelvic leak and salvage 293 Richard Guy Section F: Surprise cases 297 49 Radiology 0, Pathology 1 299 Sara Q. Warraich, Marcus Chow & Oliver Jones 50 An appendix mass? 304 Richard Guy 51 A worrying-looking rectal ulcer 307 Charles Evans 52 Think the unthinkable 310 Bruce George Section G: New technologies and techniques 313 Oliver Jones Index 325

Read more less

Book SynopsisSexual dysfunction affects men of all ages and incidence rates are expected to double by 2025 resulting in a major health burden. Though normal sexual function is an important aspect of health and well-being, sadly, this common condition still carries an associated stigma. As a result, affected men are often reluctant to approach their doctor and, instead, may live for many years with sexual dysfunction, often to the detriment of their personal lives. Male Sexual Dysfunction: A Clinical Guide covers all the common problems encountered by the clinician in this rapidly expanding and developing field. With full color throughout, this easy to read guide provides a comprehensive and systematic approach to patient management. Packed with key features, every chapter will contain flow diagrams and algorithms, key points, clinical pearls, ?what to avoid? boxes, and numerous tables, graphs and photographs . This book provides: Comprehensive focus on the core clinTable of ContentsList of contributors, vii Foreword, x 1 Epidemiology of male sexual dysfunction 1 Raanan Tal 2 Physiology of ejaculation 8 Marcel D. Waldinger 3 Physiology of penile erection 14 Uwais B. Zaid, Xiaoyu Zhang, and Tom F. Lue 4 Anatomy of penile erection 22 Lindsay Yuh and Alan Shindel 5 Endocrinology of male sexual dysfunction 30 Salim Janmohamed and Pierre‐Marc G. Bouloux 6 Pharmacology of drugs used for the treatment of erectile dysfunction 48 Ian Eardley 7 Pharmacology of drugs used in premature ejaculation 56 Michael Grant Wyllie 8 Cardiovascular risk and erectile dysfunction 62 Graham Jackson 9 The evaluation of the patient with erectile dysfunction 69 Geoffrey Hackett 10 Endocrinological investigation of men with erectile dysfunction 79 Giovanni Corona, Linda Vignozzi, and Mario Maggi 11 Duplex ultrasonography and its role in the assessment of male sexual dysfunction 91 Conrad von Stempel and Miles Walkden 12 MRI in men with sexual dysfunction 102 Alex Kirkham 13 The metabolic syndrome and ED 109 Mark Paulos and Martin Miner 14 Psychological assessment of patients with ED 120 Catherine Benedict and Christian J. Nelson 15 Nocturnal penile tumescence study 129 Chi‐Ying Li, Stephen Larsen, and Tet Yap 16 Psychosexual therapy for male sexual dysfunction 133 Angela Gregory 17 Treatment of premature ejaculation and ejaculatory disorders 143 Michael Kirby 18 Erectile dysfunction and infertility 152 Vikram Soni, Alexander W. Pastuszak, and Mohit Khera 19 Drug therapy for erectile dysfunction 172 Francisco J. Garcia, Eric Chung, and Gerald Brock 20 Priapism 194 Varun Sahdev, David Ralph, and Asif Muneer 21 Management of erectile dysfunction after pelvic surgery 203 Kelly A. Chiles and John P. Mulhall 22 Management of erectile dysfunction in men with diabetes 210 Marc Lucky, Suks Minhas, and Jas Kalsi 23 Management of erectile dysfunction in neurological patients 220 Katarina Ivana Tudor and Jalesh N. Panicker 24 Non‐surgical therapy for Peyronie’s disease 229 Rowland Rees and Victoria Dawson 25 Micropenis and penile dysmorphobia: diagnosis, management, outcomes, and future developments in the field 236 Oliver Kayes, Lizzie Chandra, and Andrew Yates 26 Surgical treatment of Peyronie’s disease 246 Ates Kadioglu and Emre Salabas 27 Penile implant surgery 258 Patrick Selph and Culley Carson 28 Vascular surgery for erectile dysfunction 270 Ronny B.W. Tan and Wayne J.G. Hellstrom 29 Penile cancer 276 Majid Shabbir and Paul K. Hegarty 30 Penile reconstruction and trauma 283 C.J. Shukla and Suks Minhas 31 Disorders of sex development 294 Dan Wood 32 Sexual dysfunction and prostate cancer therapy 302 Ashley Ridout, Mark Emberton, and Caroline Moore 33 Assessment and management of the male to female transgender patient 314 Tina G. Rashid, Phillip Thomas, and James Bellringer Index 323

Read more less

Book SynopsisClinical Oncology and Error Reduction fills a gap - the lack of a single volume on medical error in the vast field of cancer care - that has existed since a 1999 Institute of Medicine s report introduced the term medical error as a topic for doctors and patients alike. The volume, edited by Antonella Surbone, M.D.Table of ContentsList of contributors vii Foreword ix Preface xiii Acknowledgment xv 1 Introduction to oncology and medical errors 1Antonella Surbone and Michael Rowe Part I Medical errors and oncology: background and context 2 Recognizing and facing medical errors: the perspective of a physician who is also the patient 17Itzhak Brook 3 Psychological and existential consequences of medical error for oncology professionals 29Mary J. Chalino, Evelyn Y.T. Wong, Bradley L. Collins, and Richard T. Penson 4 To sue or not to sue: restoring trust in patient–doctor–family relationships 51Michael Rowe and Antonella Surbone Part II Improving patient safety in clinical oncology practice 5 Prevention of errors and patient safety: oncology nurses’ perspectives 67Martha Polovich 6 Prevention of errors and patient safety from the oncologist’s perspective 87Meghan E. C. Shea, Nie Bohlen, and Inga T. Lennes 7 Disclosing harmful medical errors 101Walter F. Baile and Daniel Epner 8 Do cross-cultural differences influence the occurrence and disclosure of medical errors in oncology? 111Lidia Schapira, Joseph R. Betancourt, and Alexander R. Green Part III Cancer patients, oncology professionals, and institutions against medical errors 9 Prevention of errors and patient safety: institutional perspectives 127Eric Manheimer 10 Professional and ethical responsibilities in adverse events and medical errors: discussions when things go wrong 145Patrick Forde and Albert W. Wu 11 Medical error and patient advocacy 158Juanne N. Clarke, PhD 12 Conclusion: the “given” and “therefores” of clinical oncology and medical errors 172Antonella Surbone and Michael Rowe Index 181

Read more less

Book SynopsisA complete guide to non-invasive imaging techniques in cardiology Today?s imaging technologies offer cardiologists more ways than ever to diagnose conditions of the heart without the need of endoscopies and other invasive procedures. Now in its third edition,Cardiac CT, PET and MRI continues to provide an in-depth explanation of these tools and their correct applications, while also exploring cardiac imaging?s most recent and groundbreaking developments. This wide-ranging guide places CT, PET and MRI in a practical context, illustrating clearly their respective functions as they apply to specific cardiological disorders and clinical situations. With the addition of seven new chapters, it also offers an expanded insight into PET ? an increasingly popular and affordable diagnostic utility, hitherto underexplored in texts devoted to imaging. Cardiac CT, PET and MRI includes: Clinically focused examinations of CT, PET and MRTable of ContentsContributors vii Foreword xiRobert O. Bonow 1 Positron Emission Tomography 1Juan Jose Vaquero and Stephen L. Bacharach 2 Cardiovascular Magnetic Resonance 38Joseph Selvanayagam, Gaetano Nucifora, and Stefan Neubauer 3 Cardiac Computed Tomography 91Dahlia Banerji, Sandeep Hedgire, and Udo Hoffmann 4 PET Myocardial Perfusion Imaging: Progress in Quantitative Assessment of Blood Flow and Flow Reserve 129Thomas H. Schindler, Ines Valenta, and Vasken Dilsizian 5 PET Imaging of Myocardial Metabolism in Health and Disease 175Robert J. Gropler and Linda R. Peterson 6 PET Imaging of Autonomic Innervation and Receptors 203James T. Thackeray and Frank M. Bengel 7 Cardiovascular Magnetic Resonance Angiography 236R. Reeve Ingle, Amr A. Youssef , Dwight G. Nishimura, and Phillip C. Yang 8 CMR to Assess Morphology, Function, Perfusion, and Viability 282Himanshu Gupta, Oleg F. Sharifov, Heewon Kim, Kuncheng Li, and Gerald M. Pohost 9 Cardiac CT for Coronary Imaging 327Marisa Lubbers and Koen Nieman 10 Multislice CT: Myocardial Function, Perfusion, and Viability 345Raymond T. Yan, Richard T. George, and Joao A. C. Lima 11 Cardiac CT and MR for the Evaluation of Acute Chest Pain in the Emergency Setting 366Nupur Verma, Tan‐Lucien Mohammed, and Charles S. White 12 Noninvasive Imaging of High‐Risk Plaque 388Amir Ahmadi, Farouc A. Jaffer, and Jagat Narula 13 Molecular Imaging Targets in Heart Failure and Left Ventricular Remodeling 405Nabil E. Boutagy, Attila Feher, Saad Sikanderkhel, and Albert J. Sinusas 14 Nuclear Imaging Guidance for Ablation of Ventricular Arrhythmias 436John Duell, Mark F. Smith, Wengen Chen, Vasken Dilsizian, and Timm‐Michael L. Dickfeld Index 450

Read more less

Book SynopsisA complete guide to the surgical techniques used to treat childhood skin conditions Recent advances have expanded the role of pediatric dermatologic surgery in both specialist and primary care settings. However, such surgeries can pose unique challenges to trainees and experienced practitioners alike. Procedures are carried out under local anesthesia and can be a source of distress and concern among young patients. Moreover, child's skin poses its own set of complicating factors, making the business of performing these procedures especially delicate and precise. This bookprovides a step-by-step primer on invasive and non-invasive treatments of childhood skin disorders, offering concise and clearly illustrated guidance on current methods and best practices. Addressing conditions' effects, the impact of recent developments in their treatment, the ethics of operative procedures on children, and multiple treatment options for childhood dermatologic disease,Pediatric Dermatologic SurgeryTable of ContentsList of Contributors vii 1 The Embryogenesis of the Skin 1Jasem Alshaiji 2 Basic Structure and Function of the Neonatal, Infantile, and Childhood Skin 13Nawaf Almutairi 3 Approach to the Child as a Patient 23Nawaf Almutairi 4 Preoperative and Postoperative Care of Children Undergoing Pediatric Dermatology Procedures 31Alanna F. Bree 5 The Pediatric Surgical Tray 37V.M. Carlberg and J.L. Fewkes 6 Anesthesia for Children 49Marcia Hogeling 7 Skin Biopsy Techniques 63Grace Sun 8 Common Pediatric Dermatologic Surgery Procedures 73Meagan Barrett, Nicole Harter, and Ashley Wysong 9 Suturing Techniques 93Israel D. Andrews, Jennifer J. Schoch, and Kathryn Ann Potter 10 Wound Closure Technique 105Daniel Belkin and Ashley Wysong 11 Wound Closure Material 115V.M. Carlberg and J.L. Fewkes 12 Dressings 125Grace Sun 13 Nail Surgery 131Jane Sanders Bellet 14 Complications of Surgery and Invasive Procedures 143Yoon Cohen and Harper N. Price 15 Improving Scars 161Harper N. Price and Maria Princesa P. Curtis 16 Special Dermatologic Surgery 171Ramin Fathi, James William Behan, and Meena Julapalli 17 Lasers for Vascular Lesions 189Nawaf Almutairi and Jasem Alshaiji 18 Lasers for Scars and Striae 197Sebastian Verne, Robert Magno, Ariel Eber, Marina Perper, Ibrahim Alomair, Abdulkareem Alfuraih, Mana Alharbi, and Keyvan Nouri 19 Lasers for Acne 207Mohammad‐Ali Yazdani Abyaneh, Robert D. Griffith, Leyre Falto‐Aizpurua, Harleen Arora, and Keyvan Nouri 20 Laser for Verrucae 223Ariel Eber, Marina Perper, Sebastian Verne, Robert Magno, Mana Alharbi, Ibrahim Alomair, Abdulkareem Alfuraih, Ali Rajabi‐Estarabadi, and Keyvan Nouri 21 Lasers and Lights for Onychomycosis 229Elizabeth Yim, Leyre A. Falto‐Aizpurua, Jennifer Ledon, and Keyvan Nouri 22 Lasers for Pigmented Lesions 241Harleen Arora, Leyre Falto‐Aizpurua, Ali Rajabi‐Estarabadi, and Keyvan Nouri 23 Lasers for Tattoos 257Stephanie Mlacker, Leyre Falto‐Aizpurua, Colin McNamara, and Keyvan Nouri 24 Lasers for Hair Removal 273Fleta Netter Bray, Leyre Falto‐Aizpurua, Robert D. Griffith, Brian Simmons, Ali Rajabi‐Estarabadi, and Keyvan Nouri 25 Lasers for Other Specific Dermatologic Disorders 289Leyre Falto‐Aizpurua, Mohammad‐Ali Yazdani Abyaneh, Harleen Arora, Robert D. Griffith, Ali Rajabi‐Estarabadi, and Keyvan Nouri 26 Medical Ethics and Bioethics in Pediatric Dermatology 303Katlein França, Tulsie Narendra Patel, Shailee Bipin Patel, and Keyvan Nouri Index 315

Read more less

Book SynopsisThis unique textbook deals with the variations in the causes, presentations and treatment of neurological disease throughout human populations. International Neurology is an indispensable guide to the full range of neurological conditions you will see in your ever-changing patient population. Comprehensive coverage of neurological diseases and disorders with a clinical approach to diagnosis, treatment and management Truly international authorship distils expert knowledge from around the world Succinct, bite-sized, templated chapters allow for rapid clinical referral Further reading recommendations for each chapter guide readers requiring more depth of information Endorsed by the World Federation of Neurology Table of ContentsList of contributors Foreword Endorsement from the World Federation of Neurology Preface Part 1 Vascular 1 Overview of StrokeChristopher Li-Hsian Chen, Chung Y. Hsu 2 Ischemic Stroke and Transient Events, TIALidia Yamada, Shelly Ozark, Bruce Ovbiagele 3 Atherothrombotic DiseaseNijasri C. Suwanwela 4 Occlusion Disease of Small Penetrating ArteriesMarie Dagonnier, Takeshi Iwanaga, Hock L. Teoh, Jorge A. Zavala, Geoffrey A. Donann 5 Ischemic White Matter Disease (Binswanger’s disease)Saltanat U. Kamenova, Aida M. Kondybayeva, Assiya Akanova 6 Brain EmbolismBernard P. L. Chan, N. Venketasubramanian, Chung Y. Hsu 7 Systemic Hypotensive Injury (Border Zone Infarction)Thomas W. Leung 8 Dissection of the Cervicocerebral ArteriesNijasri C. Suwanwela 9 Coagulation DisordersKay Sin Tan 10 Hemorrhagic StrokesAnna Katharina Flügel, Thorsten Steiner, Josef Schill, Nauman Jahangir, Morad Chughtai, Mushtaq H. Qureshi, Adnan I. Qureshi 11 Strokes in Children and Young AdultsAlfred Lindner, Ute Berweiler 12 Other Cerebrovascular SyndromesDavid J. Blacker 13 Cerebral Venous DiseasePatrick W. Carney, Stephen M. Davis 14 Spinal Cord StrokesRohini Bhole, Louis R. Caplan Part 2 Disorders of Cerebrovacular Autonomic Control 15 Reversible Cerebral Vasoconstrictive Syndrome (RCVS)Shih-Pin Chen, Shuu-Jiun Wang 16 Posterior Reversible Encephalopathy Syndrome (PRES)Pratik Bhattacharya Part 3 The Vasculitides Inflammatory vasculopathy 17 Extracranial and Intracranial Granulomatous Arteritis (Giant cell arteritis)Gregory P. Van Stavern 18 Intracranial granulomatous Arteritis (primary Angiitis of the CNS)/ Idiopathic CNS VasculitisDonald Silberberg 19 Takayasu’s ArteritisYasuhisa Kitagawa 20 Polyarteritis Nodosa, Churg-Strauss and Overlap Vasculitis SyndromeArnold I. Levinson, Robert P Lisak 21 Granulomatosis with Polyangiitis (GPS)Gerard Said 22 Cerebrovascular Disease Associated with Antiphospholipid AntibodyAdrian Marchidann, Steven R. Levine 23 Thromboangiitis Obliterans – Buerger diseaseKumar Rajamani 24 Susac’s diseaseRachel E. Ventura, Steven L. Galetta Part 4 Inflammatory Vasculopathies 25 SLE, Rheumatoid arthritis, Sjögren’s syndromeMarc Gotkine, Oded Abramsky 26 Progressive Systemic SclerosisHo Jin Kim, Jae-Won Hyun 27 Mixed connective tissue disordersHo Jin Kim, Jae-Won Hyun 28 Micro vasculitides and Behcet’s diseaseUgur Uygunoglu, Sabahattin Saip, Aksel Siva 29 SarcoidosisBarney J. Stern 30 Autoimmune Encephalitis with Neuronal Cell Surface AntibodiesJosep Dalmau, Myrna R. Rosenfeld Part 5 Paroxysmal disorders 31 Epilepsy OverviewAndres M. Kanner, Barbara E. Swartz 32 Cryptogenic and Symptomatic Generalized Epilepsies and SyndromesMarco T. Medina, Antonio V. Delgado-Escueta, Luis C. Rodríguez Salinas, Marco Medina-Montoya, Barbara E Swartz 33 Genetic (primary) Idiopathic Generalized EpilepsiesAfawi Zaid, Altynshash Jaxybayeva 34 Localization Related EpilepsiesHirokazu Oguni, Chrysostomos P. Panayiotopoulos 35 Neurodiagnostic Tools for the Paroxysmal DisordersBarbara E. Swartz 36 Neuropharmacology of Antiepileptic DrugsPaul B. Pritchard, III 37 Surgical and Other TreatmentIvan Rektor, Barbara E. Swartz Part 6 Dementia 38 Dementia OverviewMurray Grossman 39 Mild cognitive impairment to include amnestic mild cognitive impairment and Alzheimer’s diseaseDavid Wolk, Sanjeev Vaishnavi 40 Parkinson's Dementia, Lewy Body Disease and Other SynucleinopathiesIrena Rektorová, Marek Baláž, Robert Rusina, Radoslav Matìj 41 Specific Vascular SyndromesElka Stefanova, Vladimir Kostiæ 42 Vascular cognitive ImpairmentElka Stefanova, Vladimir Kostiæ 43 Frontotemporal dementiaKatya Rascovsky, Diana Matallana 44 Progressive Supranuclear Palsy, Corticobasal Syndrome and Other TauopathiesDavid J. Irwin 45 Amyotrophic Lateral Sclerosis and Other TDP-43 ProteinopathiesAlbert C. Ludolph 46 Metabolic, toxic, infectious, inflammatory and other dementiasJohn M. Ringman, Arousiak Varpetian, Yu-Wei Lin Part 7 Movement Disorders 47 Movement disorders: An overviewRoongroj Bhidayasiri, Jirada Sringean, Daniel D. Truong 48 TremorJan Raethjen, Günther Deuschl 49 ParkinsonismDronacharya Lamichhane, Lisa M. Shulman 50 Parkinson’s diseaseDaniel D. Truong, Roongroj Bhidayasiri 51 DystoniaStanley Fahn 52 Chorea and related disordersRoongroj Bhidayasiri, Onanong Jitkritsadakul, Daniel D. Truong 53 MyoclonusJohn N. Caviness, Daniel D. Truong 54 Tics and Tourette syndromeValerie Suski, Mark Stacy 55 AtaxiaSergey N. Illarioshkin 56 Drug induced movement disordersRick Stell 57 Paroxysmal movement disordersSopio Sopromadze, Alexander Tsiskaridze Part 8 Infectious diseases Bacterial infections 58 Acute bacterial meningitisSudesh Prabhakar 59 Brain abscessGagandeep Singh 60 Subdural empyemaSandi Lam, Eric Momin 61 Epidural abscessSandi Lam, Humphrey Okechi, Jared Fridley 62 Intracranial septic thrombophlebitisIsmail A. Khatri, Mohammad Wasay 63 Encephalitis due to bacterial infectionsKaren L. Roos, Jennifer Durphy Mycobacterial infections 64 Mycobacterium tuberculosis and aviumEinar P. Wilder-Smith 65 LeprosyMinh Le, Minh Hoang Van Spirochetal infections 66 NeurosyphilisJonathan Carr 67 Lyme diseasePatricia K. Coyle Protozoan diseases 68 Introduction to protozoans of the central nervous systemMarylou V. Solbrig 69 Amoebic disease of the central nervous systemMelanie Walker 70 Toxoplasmosis of the central nervous systemMarylou V. Solbrig 71 Cerebral malariaPolrat Wilairatana, Srivicha Krudsood, Noppadon Tangpukdee 72 TrypanosomiasisFrancisco Javier Carod-Artal Helminthic 73 CestodesOscar H. Del Brutto 74 Trematodes: schistosomiasisManjari Tripathi 75 NematodesManjari Tripathi Other infection 76 Fungal infections of the central nervous systemThomas Cesario 77 Rickettsial diseaseKelly J Baldwin, Narendra Rathi Part 9 Prion diseases and Neurovirology 78 Prion DisordersEllen Gelpi, Herbert Budka 79 Acute and recurrent viral meningitisLarry E. Davis 80 Acute viral encephalitisHeng Thay Chong, Chong Tin Tan 81 Neurologic complications of human herpes virus infectionsDon Gilden, Maria A. Nagel 82 Chronic viral diseases of the CNSMaria A. Nagel, Don Gilden 83 Progressive multifocal leukoencephalopathy, PMLSalim Chahin, Thomas Weber, Joseph R. Berger HIV and the Nervous System 84 Biology of the HIV Virus and overview of AIDSAlexandros C. Tselis 85 HIV encephalitis and myelopathyGirish Modi, Kapila Hari, Andre Mochan 86 Neuromuscular complications of HIVDavid M. Simpson, Kara Stavros 87 Opportunistic Infections in HIV Positive Subjects and AIDS patientsB. J. Brew, A. Laffan 88 Neurologic Complications of HTLV-1Abelardo Q-C Araujo, Marco A. Lima, Marcus Tulius Silva Part 10 Demyelinating Disorders 89 Multiple sclerosisRobert P. Lisak, Jun-Ichi Kira 90 Multiple sclerosis in childrenSarah E. Hopkins, Yael Hacohen, Sona Narula, Brenda L Banwell 91 Neuromyelitis opticaWilliam M. Carroll 92 Acute disseminated encephalomyelitisSona Narula, Sarah E. Hopkins, Yael Hacohen, and Brenda Banwell 93 Isolated inflammatory demyelinating CNS syndromesErnest Willoughby 94 Osmotic demyelination syndromesOvidiu-Alexandru Bajenaru 95 Concentric sclerosisTakeshi Tabira Part 11 Specific toxicities and deficiencies 96 ToxicologyChin-Chang Huang, Nai-Shin Chu 97 Alcohol related neurological disordersYuri Alekseenko 98 Vitamin DeficienciesJacques Serratrice, Volodymyr Golyk 99 Starvation, Strachan syndrome and postgastroplasty syndromeIvan Milanov, Vesselina Grozeva Part 12 Peripheral Neuropathies 100 Peripheral Neuropathies overviewFriedhelm Sandbrink 101 Hereditary neuropathiesLiying Cui, Mingsheng Liu 102 Acquired NeuropathiesFriedhelm Sandbrink 103 PlexopathiesFriedhelm Sandbrink Part 13 Neuromuscular DisordersHereditary Neuromuscular DisordersDegenerative upper and lower motor neuron disorders 104 Amyotrophic Lateral Sclerosis (ALS)Björn Oskarsson, Nanette Joyce, Steven P. Ringel 105 Progressive Muscular Atrophy (PMA)James Ha, Steven P. Ringel, Björn Oskarsson 106 Primary Lateral Sclerosis (PLS)Nanette Joyce, Björn Oskarsson, Yvonne D. Rollins, Steven P. Ringel 107 Hereditary spastic paraplegiaIldefonso Rodríguez-Leyva 108 Spinal muscular atrophySabine Rudnik-Schöneborn, Klaus Zerres 109 Post-polio syndromeNils Erik Gilhus Degenerative Muscle Disorders 110 Limb girdle muscular dystrophies (LGMD)A. J. van der Kooi, M. de Visser 111 DystrophinopathiesChiara S. M. Straathofa, Marianne de Visserb 112 Facioscapulohumeral dystrophy (FSHD)George W. Padberg 113 Myotonic disordersGiovanni Meola, Rosanna Cardani 114 Oculopharyngeal Muscular Dystrophy (OPMD)Luis A. Chui, Tahseen Mozaffar, Namita A. Goyal 115 Emery Dreifuss and other laminopathiesMalcolm Rabie, Yoram Nevo 116 Muscle channelopathiesKaren Suetterlin, Michael G. Hanna 117 Congenital dystrophies and myopathiesYoung-Chul Choi 118 Congenital myasthenic syndromes (CMS)Angela Abicht, Ulrike Schara 119 Distal myopathiesPhillipa J. Lamont, Nigel G. Laing Acquired Neuromuscular Disorders 120 PolymyositisMarinos C. Dalakas 121 DermatomyositisMarinos C. Dalakas 122 Inclusion body myositis (IBM)Merrilee Needham, Frank L. Mastaglia 123 Immune mediated inflammatory myopathiesWerner Stenzel, Hans-Hilmar Goebel, Olivier Benveniste, Yves Allenbach 124 Toxic myopathiesStefen Brady, David Hilton-Jones 125 Critical illness neuromuscular disordersNicola Latronico, Frank A. Rasulo 126 Exercise intolerance and myoglobinuriaJohn Vissing 127 Muscle crampsKimiyoshi Arimura, Raymond L. Rosales 128 Myasthenia gravisRichard A. Lewis 129 LEMSEmilia Kerty 130 NMJ disorders caused by drugs and toxinsZohar Argov Part 14 Neurogenetic 131 NeurogeneticKaren P. Frei, Janice Fuentes Part 15 Neurootology 132 NeurootologyKevin A. Kerber Part 16 Neuroophthalmology 133 NeuroophthalmologyAnuchit Poonyathalang Part 17 Neuro-oncology 134 Neuro-oncology overviewMarc C. Chamberlain Glial tumors 135 High grade astrocytomasOlivier-L Chinot, Marc C. Chamberlain 136 Low grade astrocytomasM.J. van den Bent 137 Low grade and anaplastic oligodendrogliomaSergio Cabrera, Catherine Maurice, Warren P. Mason 138 Brain stem gliomaIra J. Dunkel, Mark M. Souweidane 139 Intracranial ependymomaMarc C. Chamberlain Non-glial tumors 140 Nerve sheath tumorsNathan J. Ranalli, Zarina S. Ali, Gregory G. Heuer, Eric L. Zager 141 MeningiomasJeffrey Raizer, Simran Singh 142 MedulloblastomaAlba A. Brandes, Regina I. Jakacki, Enrico Franceschi 143 Primary central nervous system lymphoma (PCNSL)Deborah T. Blumenthal, Idan Ben-Horin Metastatic tumors 144 Brain metastasesBabita Jyoti, Farida Balkhi Alam, Silvia Hofer, Michael Brada 145 Leptomeningeal metastasesEmilie Le Rhun, Sophie Taillibert, Marc C. Chamberlain 146 Spinal epidural metastasesRoberta Rudà, Riccardo Soffietti Neurologic complications of systemic cancer147 General approach to the diagnosis and treatment of paraneoplastic neurological disordersMyrna R. Rosenfeld, Josep Dalmau Part 18 Sleep disorders 148 InsomniaDelwyn J. Bartlett, Colin A. Espie Primary disorders of daytime somnolence 149 NarcolepsyMarcel Hungs 150 Idiopathic hypersomniaMarcel Hungs 151 Obstructive Sleep ApneaJanesh Patel, Christian Guilleminault 152 Restless Leg syndrome and Periodic Limb Movement DisordersBirgit Högl, Birgit Frauscher, Claudio Podesta 153 Circadian sleep disordersSergio Tufik, Lia R .A. Bittencourt, Monica L. Andersen Parasomnias 154 Arousal disordersLi Ling Lim 155 REM Sleep Behavioral DisordersLi Ling Lim 156 Hypnogenic paroxysmal DystoniaCynthia L. Comella 157 Sleep abnormalities in Neurological DisordersMargaret Park, Cynthia L. Comella Part 19 Spinal cord 158 Spinal cord disordersDavid B. Vodušek, Miran Jeromel, Simon Podnar 159 Ischemic and congestive myelopathiesSimon Podnar, Miran Jeromel, David B. Vodušek 160 SyringomyeliaAlla Guekht Part 20 Pediatric neurology 161 Neonatal neurologyMary Payne, Ann Tilton 162 Neurodevelopmental disordersAdam L. Numis, Raman Sankar 163 Floppy infant syndromeJong-Hee Chae, Anna Cho 164 Storage disordersJeffrey J. Ekstrand, Jason T. Lerner, Raman Sankar 165 Fatty acid oxidation disordersThomas Wieser 166 Disorders of amino acid, organic acid, and ammonia metabolismStephen Cederbaum 167 Pediatric neurotransmitter diseasesStephen Deputy 168 Mitochondrial encephalomyopathiesStacey K. H. Tay, Caterina Garone, Salvatore DiMauro 169 Disorders resulting from transportersAnna Czlonkowska, David Gloss, Tomasz Litwin 170 The porphyriasF. J. E. Vajda Part 21 CNS Trauma, Pain and Headache 171 Traumatic brain injuryChristopher C. Giza 172 Spinal InjuryEnver I. Bogdanov, Aisylu T. Faizutdinova 173 Whiplash injuryAnthony Ciabarra 174 Decompression sicknessAndreas Koch, Günther Deuschl 175 PainGuillermo García-Ramos, Bernardo Cacho-Díaz, Bruno Estañol-Vidal 176 HeadacheStephen D. Silberstein 177 Facial and neck painKammant Phanthumchinda 178 Chronic Fatigue SyndromeJasem Yousef Al-Hashel 179 FibromyalgiaSaeed Bohlega, Hussam Abou Al-Shaar Index

Read more less

Book SynopsisSoft tissue problems are very common, with one in four people at any one time suffering with a musculoskeletal disorder. ABC of Soft Tissue Disorders is a practical, fully illustrated guide to their assessment and treatment.Table of ContentsList of Contributors, vii 1 Introduction to Musculoskeletal Medicine, 1Jim Wardrope 2 Soft Tissue Problems of the Neck, 12Michael Athanassacopoulos and Neil Chiverton 3 Back Pain, 19Ben Cooper, Richard J. Follett and Neil Chiverton 4 Shoulder: Sub-acromial Pathology, 25Lennard Funk 5 Shoulder:The Articular Structures, 33Lennard Funk 6 Elbow, 40David Stanley and Santosh Venkatachalam 7 Soft Tissue Disorders at the Wrist, 45David Knott 8 Soft Tissue Injuries of the Hand, 50Helen Cugnoni 9 Common Soft Tissue Disorders of the Hip, 55Alison Smeatham 10 Soft Tissue Knee Injuries, 62Paul M. Sutton 11 Non-traumatic Knee Problems, 68Jim Wardrope and Paul M. Sutton 12 Calf and Shin Problems, 72Roger Dalton, Mark B. Davies and Ashley Jones 13 Soft Tissue Injuries of the Ankle, 77Hasan Qayyum, Chris M. Blundell and Joanna Ollerenshaw 14 The Foot, 84Sherif Hemaya and Carolyn Chadwick Index, 89

Read more less

Book SynopsisA clinical guide to transplantation in lymphoma to present advanced knowledge on how to integrate, transplantat and other novel therapies in patients with lymphoid malignancies. It provides practical management guidance on how to integrate, transplant and other novel therapies in patients with lymphoid malignancies.Trade ReviewSir William Osler is reputed to have said, “Listen to the patient and he will give you the answer.” Had he been alive now and practicing transplantation for lymphoma, he could have well said “Read the Clinical Guide to Transplantation in Lymphoma and it will give you the answer.” These reviewers are very impressed by the breadth and scope of this book edited by Drs. Bipin Savani and Mohamed Mohty, ably aided by an array of expert contributors from all over the world.Clinical Guide to Transplantation in Lymphoma is extremely easy to read and very well written. In this era ofexponential information growth this book is surprisingly current, with the latest references. It has an ambitious scope, setting out to cover all aspects of transplantation in lymphoma and managing to meet that expectation.Chapters are laid out in logical sequence divided into 2 sections. Section 1 is particularly interesting and haschapters on the historical perspective of transplantation for lymphoma, transplant data collection and reporting, and analytical methods. The remainder of section 1 describes the general principles of transplantation in lymphomas, addressing issues such as mobilization, preparative regimens, and management of the early, late, and long-term issues arising after transplantation. Some chapters include transplantation for lymphoma in children, adults, and young adolescents; pretransplant evaluation; preparative regimens for autologous and allogeneic transplants; stem cell mobilization and stem cell source; post-transplant follow-up for autologousand allogeneic transplant, and a novel chapter, “First 100 Days of the Autologous Hematopoietic Stem Cell Transplantation Process in Lymphoma.” The chapters in section 1 are broadly applicable and would prove invaluable to trainees pursuing fellowships in hematopoietic cell transplantation.Section 2 is laid out as a chapter by chapter discussion of various lymphoma histologies and the applicability of hematopoietic cell transplantation in each. One can return to some of these chapters again and again because all common and most rare lymphoma subtypes (including HIV-associated lymphoma) are discussed in excellent detail. We found each one of these chapters to be remarkably up to date. In a field such ashematopoietic cell transplantation,where there is considerable ambiguity and few randomized studies, the authors and editors have maintained a neutral and unbiased tone,discussing the available data andguidelines exhaustively.Very few similar textbooks focus on transplantation in a disease group. Clinical Guide to Transplantation in Lymphoma is concise enough, practical, and clinically oriented to be considered a practical manual but at the same time manages to be comprehensive. Some unique features in this book are the numerous excellent graphs and tables and the discussion of case studies and clinical guidelines (United States and European) wherever applicable. We found very few typographic errors. For future editions we recommend at least 1 chapter devoted to the emerging field of cellular immunotherapy.The editors and the contributors need to be congratulated for an encyclopedic work that still manages to be a ready reference guide. This book will be used extensively and should be in the library of every transplanter.We hope it runs into many future editions and becomes the authoritative textbook for transplantation in lymphoma. (Yogesh Jethava, Parameswaran Hari, University of Arkansas for Medical Science, Biology of Blood and Marrow Transplantation, Nov 2015)Table of ContentsList of contributors vii Foreword xi Introduction 1 Section 1: Transplantation in lymphomas 1 Lymphoma and transplantation: historical perspective 5Andrew R. Rezvani 2 Lymphoma: working committee and data reporting after transplantation in lymphoma 13Wael Saber, Mehdi Hamadani, Shahrukh Hashmi and Parameswaran Hari 3 Use of transplantation in lymphoma: adults 23Parastoo Bahrami Dahi, Gabriela Soriano Hobbs and Miguel]Angel Perales 4 Hematopoietic stem cell transplantation for lymphoma in children, adolescents, and young adults 31Nader Kim El]Mallawany and Mitchell S. Cairo 5 Preparative regimens for lymphoma: autologous hematopoietic stem cell transplantation 45Taiga Nishihori, Karma Z. Salem, Ernesto Ayala and Mohamed A. Kharfan]Dabaja 6 Preparative regimens for lymphoma: allogeneic hematopoietic stem cell transplantation 57Mohamed A. Kharfan]Dabaja, Najla El]Jurdi, Mehdi Hamadani and Ernesto Ayala 7 Pretransplantation evaluation, comorbidities, and nondisease]related eligibility criteria for transplantation in lymphoma, 69Melissa Logue 8 Stem cell mobilization in lymphoma patients 75Tarah Ballinger, Bipin N. Savani and Mohamad Mohty 9 Allogeneic hematopoietic stem cell transplantation for lymphoma: stem cell source, donor, and HLA matching 85Michael Green and Mitchell Horwitz 10 Management of early and late toxicities of autologous hematopoietic stem cell transplantation 93Sai Ravi Pingali and Yago Nieto 11 Long]term follow]up of lymphoma patients after allogeneic hematopoietic cell transplantation 103Shylaja Mani and Navneet S. Majhail 12 First 100 days of the autologous hematopoietic stem cell transplantation process in lymphoma 109Angela Moreschi Woods 13 First 100 days of the allogeneic hematopoietic stem cell transplantation process in lymphoma 113Angela Moreschi Woods Section 2: Management 14 Stem cell transplantation in follicular lymphoma,119Satyajit Kosuri and Koen Van Besien 15 Chronic lymphocytic leukemia/small lymphocytic lymphoma 133Salyka Sengsayadeth and Wichai Chinratanalab 16 Diffuse large B]cell lymphoma 145Lauren Veltri, Bipin N. Savani, Mohamed A. Kharfan]Dabaja, Mehdi Hamadani and Abraham S. Kanate 17 Mantle cell lymphoma 161Sascha Dietrich and Peter Dreger 18 Hodgkin lymphoma 173Eva Domingo]Domenech and Anna Sureda 19 Peripheral T]cell lymphomas 187Giulia Perrone, Chiara De Philippis, Lucia Farina and Paolo Corradini 20 Transplantation in Burkitt and lymphoblastic lymphoma 201Gregory A. Hale 21 Transplantation in adult T]cell leukemia/lymphoma 209Ali Bazarbachi and Olivier Hermine 22 Hematopoietic cell transplantation for HIV]related lymphomas 217Joseph C. Alvarnas 23 Stem cell transplantation for mycosis fungoides/Sézary syndrome 233Eric D. Jacobsen 24 Role of transplantation in lymphoplasmacytic lymphoma 241Silvia Montoto and Charalampia Kyriakou 25 Transplantation outcome in primary mediastinal large B]cell lymphoma 247Amanda F. Cashen 26 Management of post]transplant lymphoproliferative disorders 253Jan Styczynski and Per Ljungman Appendix I Follow]up calendar after autologous stem cell transplantation in lymphoma 261Angela Moreschi Woods Appendix II Follow]up calendar after allogeneic stem cell transplantation in lymphoma 263Angela Moreschi Woods Index 265

Read more less

Book SynopsisThe two Medical Sciences at a Glance titles - Medical Sciences at a Glance (9781118360927) and Medical Sciences at a Glance: Practice Workbook (9780470654491) - together at a specially-discounted priceProvides a complete, concise, and accessible introduction to the medical sciences

Read more less

Book SynopsisCritical Observations in Radiology for Medical Students is an ideal companion for medical students and clinicians, with a focus on medical learning and patient management to support clerkship rotations and internship training.Table of ContentsContributors vi Preface vii About the companion website viii 1 Basic principles of radiologic modalities 1Mamdoh AlObaidy Kiran Reddy Busireddy and Richard C. Semelka 2 Imaging studies: What study and when to order? 10Kiran Reddy Busireddy Miguel Ramalho and Mamdoh AlObaidy 3 Chest imaging 27Saowanee Srirattanapong and Katherine R. Birchard 4 Cardiac imaging 49Nicole T. Tran and J. Larry Klein 5 Abdominopelvic imaging 65Pinakpani Roy and Lauren M.B. Burke 6 Brain imaging 96Joana N. Ramalho and Mauricio Castillo 7 Spine imaging 116Joana N. Ramalho and Mauricio Castillo 8 Head and neck imaging 136Joana N. Ramalho Kiran Reddy Busireddy and Benjamin Huang 9 Musculoskeletal imaging 163Daniel B. Nissman Frank W. Shields IV and Matthew S. Chin 10 Breast imaging 201Susan Ormsbee Holley 11 Pediatric imaging 213Cassandra M. Sams 12 Interventional Radiology 235Ari J. Isaacson Sarah Thomas J.T. Cardella and Lauren M.B. Burke Index 253

Read more less

Book SynopsisUltrasound Elastography for Biomedical Applications and Medicine Ivan Z. Nenadic, Matthew W. Urban, James F.Table of ContentsList of Contributors xix Section I Introduction 1 1 Editors’ Introduction 3Ivan Nenadic, Matthew Urban, James Greenleaf, Jean-Luc Gennisson,Miguel Bernal, and Mickael Tanter References 5 Section II Fundamentals of Ultrasound Elastography 7 2 Theory of Ultrasound Physics and Imaging 9Roberto Lavarello andMichael L. Oelze 2.1 Introduction 9 2.2 Modeling the Response of the Source to Stimuli [h(t)] 10 2.3 Modeling the Fields from Sources [p(t, x)] 12 2.4 Modeling an Ultrasonic Scattered Field [s(t, x)] 15 2.5 Modeling the Bulk Properties of the Medium [a(t, x)] 19 2.6 Processing Approaches Derived from the Physics of Ultrasound [Ω] 21 2.7 Conclusions 26 References 27 3 Elastography and the Continuum of Tissue Response 29Kevin J. Parker 3.1 Introduction 29 3.2 Some Classical Solutions 31 3.3 The Continuum Approach 32 3.4 Conclusion 33 Acknowledgments 33 References 34 4 Ultrasonic Methods for Assessment of TissueMotion in Elastography 35Jingfeng Jiang and Bo Peng 4.1 Introduction 35 4.2 Basic Concepts and their Relevance in Tissue Motion Tracking 36 4.3 Tracking Tissue Motion through Frequency-domain Methods 37 4.4 Maximum Likelihood (ML) Time-domain Correlation-based Methods 39 4.5 Tracking Tissue Motion through Combining Time-domain and Frequency-domain Information 44 4.6 Time-domain Maximum A Posterior (MAP) Speckle Tracking Methods 45 4.7 Optical Flow-based Tissue Motion Tracking 53 4.8 Deformable Mesh-based Motion-tracking Methods 55 4.9 Future Outlook 57 4.10 Conclusions 63 Acknowledgments 63 Acronyms 63 Additional Nomenclature of Definitions and Acronyms 64 References 65 Section III Theory of Mechanical Properties of Tissue 71 5 Continuum Mechanics Tensor Calculus and Solutions toWave Equations 73Luiz Vasconcelos, Jean-Luc Gennisson, and Ivan Nenadic 5.1 Introduction 73 5.2 Mathematical Basis and Notation 73 5.3 Solutions toWave Equations 75 References 81 6 TransverseWave Propagation in Anisotropic Media 82Jean-Luc Gennisson 6.1 Introduction 82 6.2 Theoretical Considerations from General to Transverse Isotropic Models for Soft Tissues 82 6.3 Experimental Assessment of Anisotropic Ratio by ShearWave Elastography 87 6.4 Conclusion 88 References 88 7 TransverseWave Propagation in Bounded Media 90Javier Brum 7.1 Introduction 90 7.2 TransverseWave Propagation in Isotropic Elastic Plates 90 7.3 Plate in Vacuum: LambWaves 93 7.4 Viscoelastic Plate in Liquid: Leaky LambWaves 96 7.5 Isotropic Plate Embedded Between Two Semi-infinite Elastic Solids 99 7.6 TransverseWave Propagation in Anisotropic Viscoelastic Plates Surrounded by Non-viscous Fluid 100 7.7 Conclusions 103 Acknowledgments 103 References 103 8 Rheological Model-based Methods for Estimating Tissue Viscoelasticity 105Jean-Luc Gennisson 8.1 Introduction 105 8.2 Shear Modulus and Rheological Models 106 8.3 Applications of Rheological Models 113 References 116 9 Wave Propagation in ViscoelasticMaterials 118YueWang andMichael F. Insana 9.1 Introduction 118 9.2 Estimating the Complex Shear Modulus from PropagatingWaves 119 9.3 Wave Generation and Propagation 120 9.4 Rheological Models 122 9.5 Experimental Results and Applications 124 9.6 Summary 125 References 126 Section IV Static and Low Frequency Elastography 129 10 Validation of Quantitative Linear and Nonlinear Compression Elastography 131Jean Francois Dord, Sevan Goenezen, Assad A. Oberai, Paul E. Barbone, Jingfeng Jiang,Timothy J. Hall, and Theo Pavan 10.1 Introduction 131 10.2 Methods 132 10.3 Results 134 10.4 Discussion 137 10.5 Conclusions 140 Acknowledgement 141 References 141 11 Cardiac Strain and Strain Rate Imaging 143Brecht Heyde, OanaMirea, and Jan D’hooge 11.1 Introduction 143 11.2 Strain Definitions in Cardiology 143 11.3 Methodologies Towards Cardiac Strain (Rate) Estimation 145 11.4 Experimental Validation of the Proposed Methodologies 149 11.4.1 Synthetic Data Testing 150 11.5 Clinical Applications 151 11.6 Future Developments 153 References 154 12 Vascular and Intravascular Elastography 161Marvin M. Doyley 12.1 Introduction 161 12.2 General Principles 161 12.3 Conclusion 168 References 168 13 Viscoelastic Creep Imaging 171Carolina Amador Carrascal 13.1 Introduction 171 13.2 Overview of Governing Principles 172 13.3 Imaging Techniques 173 13.4 Conclusion 187 References 187 14 Intrinsic CardiovascularWave and Strain Imaging 189Elisa Konofagou 14.1 Introduction 189 14.2 Cardiac Imaging 189 14.3 Vascular Imaging 208 Acknowledgements 219 References 219 Section V Harmonic ElastographyMethods 227 15 Dynamic Elasticity Imaging 229Kevin J. Parker 15.1 Vibration Amplitude Sonoelastography: Early Results 229 15.2 Sonoelastic Theory 229 15.3 Vibration Phase Gradient Sonoelastography 232 15.4 CrawlingWaves 233 15.5 Clinical Results 233 15.6 Conclusion 234 Acknowledgments 235 References 235 16 Harmonic ShearWave Elastography 238Heng Zhao 16.1 Introduction 238 16.2 Basic Principles 239 16.3 Ex Vivo Validation 242 16.4 In Vivo Application 244 16.5 Summary 246 Acknowledgments 247 References 247 17 Vibro-acoustography and its Medical Applications 250Azra Alizad andMostafa Fatemi 17.1 Introduction 250 17.2 Background 250 17.3 Application of Vibro-acoustography for Detection of Calcifications 251 17.4 In Vivo Breast Vibro-acoustography 254 17.5 In VivoThyroid Vibro-acoustography 259 17.6 Limitations and Further Future Plans 260 Acknowledgments 261 References 261 18 Harmonic Motion Imaging 264Elisa Konofagou 18.1 Introduction 264 18.2 Background 264 18.3 Methods 267 18.4 Preclinical Studies 273 18.5 Future Prospects 277 Acknowledgements 279 References 279 19 ShearWave Dispersion Ultrasound Vibrometry 284Pengfei Song and Shigao Chen 19.1 Introduction 284 19.2 Principles of ShearWave Dispersion Ultrasound Vibrometry (SDUV) 284 19.3 Clinical Applications 286 19.4 Summary 291 References 292 Section VI Transient ElastographyMethods 295 20 Transient Elastography: From Research to Noninvasive Assessment of Liver Fibrosis Using Fibroscan® 297Laurent Sandrin,Magali Sasso, Stéphane Audière, Cécile Bastard, Céline Fournier,Jennifer Oudry, Véronique Miette, and Stefan Catheline 20.1 Introduction 297 20.2 Principles of Transient Elastography 297 20.3 Fibroscan 301 20.4 Application of Vibration-controlled Transient Elastography to Liver Diseases 306 20.5 Other Applications of Transient Elastography 309 20.6 Conclusion 310 References 311 21 From Time Reversal to Natural ShearWave Imaging 318Stefan Catheline 21.1 Introduction: Time Reversal ShearWave in Soft Solids 318 21.2 ShearWave Elastography using Correlation: Principle and Simulation Results 320 21.3 Experimental Validation in Controlled Media 323 21.4 Natural ShearWave Elastography: First In Vivo Results in the Liver, theThyroid, and the Brain 328 21.5 Conclusion 331 References 331 22 Acoustic Radiation Force Impulse Ultrasound 334Tomasz J. Czernuszewicz and Caterina M. Gallippi 22.1 Introduction 334 22.2 Impulsive Acoustic Radiation Force 334 22.3 Monitoring ARFI-induced Tissue Motion 335 22.4 ARFI Data Acquisition 340 22.5 ARFI Image Formation 341 22.6 Real-time ARFI Imaging 343 22.7 Quantitative ARFI Imaging 345 22.8 ARFI Imaging in Clinical Applications 346 22.9 Commercial Implementation 350 22.10 Related Technologies 350 22.11 Conclusions 351 References 351 23 Supersonic Shear Imaging 357Jean-Luc Gennisson andMickael Tanter 23.1 Introduction 357 23.2 Radiation Force Excitation 357 23.3 Ultrafast Imaging 362 23.4 ShearWave Speed Mapping 364 23.5 Conclusion 365 References 366 24 Single Tracking Location ShearWave Elastography 368Stephen A.McAleavey 24.1 Introduction 368 24.2 SMURF 370 24.3 STL-SWEI 373 24.4 Noise in SWE/Speckle Bias 376 24.5 Estimation of viscoelastic parameters (STL-VE) 380 24.6 Conclusion 384 References 384 25 Comb-push Ultrasound Shear Elastography 388Pengfei Song and Shigao Chen 25.1 Introduction 388 25.2 Principles of Comb-push Ultrasound Shear Elastography (CUSE) 389 25.3 Clinical Applications of CUSE 396 25.4 Summary 396 References 397 Section VII Emerging Research Areas in Ultrasound Elastography 399 26 Anisotropic ShearWave Elastography 401Sara Aristizabal 26.1 Introduction 401 26.2 ShearWave Propagation in Anisotropic Media 402 26.3 Anisotropic ShearWave Elastography Applications 403 26.4 Conclusion 420 References 420 27 Application of GuidedWaves for Quantifying Elasticity and Viscoelasticity of Boundary Sensitive Organs 422Sara Aristizabal, Matthew Urban, Luiz Vasconcelos, BenjaminWood,Miguel Bernal,Javier Brum, and Ivan Nenadic 27.1 Introduction 422 27.2 Myocardium 422 27.3 Arteries 426 27.4 Urinary Bladder 431 27.5 Cornea 433 27.6 Tendons 435 27.7 Conclusions 439 References 439 28 Model-free Techniques for Estimating Tissue Viscoelasticity 442Daniel Escobar, Luiz Vasconcelos, Carolina Amador Carrascal, and Ivan Nenadic 28.1 Introduction 442 28.2 Overview of Governing Principles 442 28.3 Imaging Techniques 443 28.4 Conclusion 449 References 449 29 Nonlinear Shear Elasticity 451Jean-Luc Gennisson and Sara Aristizabal 29.1 Introduction 451 29.2 Shocked Plane ShearWaves 451 29.3 Nonlinear Interaction of Plane ShearWaves 455 29.4 Acoustoelasticity Theory 460 29.5 Assessment of 4th Order Nonlinear Shear Parameter 465 29.6 Conclusion 468 References 468 Section VIII Clinical Elastography Applications 471 30 Current and Future Clinical Applications of Elasticity Imaging Techniques 473Matthew Urban 30.1 Introduction 473 30.2 Clinical Implementation and Use of Elastography 474 30.3 Clinical Applications 475 30.3.1 Liver 475 30.3.2 Breast 476 30.3.3 Thyroid 476 30.3.4 Musculoskeletal 476 30.3.5 Kidney 477 30.3.6 Heart 478 30.3.7 Arteries and Atherosclerotic Plaques 479 30.4 FutureWork in Clinical Applications of Elastography 480 30.5 Conclusions 480 Acknowledgments 480 References 481 31 Abdominal Applications of ShearWave Ultrasound Vibrometry and Supersonic Shear Imaging 492Pengfei Song and Shigao Chen 31.1 Introduction 492 31.2 Liver Application 492 31.3 Prostate Application 494 31.4 Kidney Application 495 31.5 Intestine Application 496 31.6 Uterine Cervix Application 497 31.7 Spleen Application 497 31.8 Pancreas Application 497 31.9 Bladder Application 498 31.10 Summary 499 References 499 32 Acoustic Radiation Force-based Ultrasound Elastography for Cardiac Imaging Applications 504Stephanie A. Eyerly-Webb,MaryamVejdani-Jahromi, Vaibhav Kakkad, Peter Hollender,David Bradway, andGregg Trahey 32.1 Introduction 504 32.2 Acoustic Radiation Force-based Elastography Techniques 504 32.3 ARF-based Elasticity Assessment of Cardiac Function 505 32.4 ARF-based Image Guidance for Cardiac Radiofrequency Ablation Procedures 510 32.5 Conclusions 515 Funding Acknowledgements 515 References 516 33 Cardiovascular Application of ShearWave Elastography 520Pengfei Song and Shigao Chen 33.1 Introduction 520 33.2 Cardiovascular ShearWave Imaging Techniques 521 33.3 Clinical Applications of Cardiovascular ShearWave Elastography 525 33.4 Summary 529 References 530 34 Musculoskeletal Applications of Supersonic Shear Imaging 534Jean-Luc Gennisson 34.1 Introduction 534 34.2 Muscle Stiffness at Rest and During Passive Stretching 535 34.3 Active and Dynamic Muscle Stiffness 537 34.4 Tendon Applications 539 34.5 Clinical Applications 541 34.6 Future Directions 542 References 542 35 Breast ShearWave Elastography 545Azra Alizad 35.1 Introduction 545 35.2 Background 545 35.3 Breast Elastography Techniques 546 35.4 Application of CUSE for Breast Cancer Detection 548 35.5 CUSE on a Clinical Ultrasound Scanner 549 35.6 Limitations of Breast ShearWave Elastography 551 35.7 Conclusion 552 Acknowledgments 552 References 552 36 Thyroid ShearWave Elastography 557Azra Alizad 36.1 Introduction 557 36.2 Background 557 36.3 Role of Ultrasound and its Limitation inThyroid Cancer Detection 557 36.4 Fine Needle Aspiration Biopsy (FNAB) 558 36.5 The Role of Elasticity Imaging 558 36.6 Application of CUSE onThyroid 561 36.7 CUSE on Clinical Ultrasound Scanner 561 36.8 Conclusion 563 Acknowledgments 564 References 564 Section IX Perspective on Ultrasound Elastography 567 37 Historical Growth of Ultrasound Elastography and Directions for the Future 569Armen Sarvazyan andMatthewW. Urban 37.1 Introduction 569 37.2 Elastography Publication Analysis 569 37.3 Future Investigations of Acoustic Radiation Force for Elastography 574 37.3.1 Nondissipative Acoustic Radiation Force 574 37.3.2 Nonlinear Enhancement of Acoustic Radiation Force 575 37.3.3 SpatialModulation of Acoustic Radiation Force Push Beams 575 37.4 Conclusions 576 Acknowledgments 577 References 577 Index 581

Read more less

Book SynopsisAccording to the International Association for Ambulatory Surgery (IAAS), ambulatory surgery should be defined as 'an operation/procedure, excluding an office or outpatient operation/procedure, where the patient is discharged on the same working day'. The rise of ambulatory surgery has been driven by technological advances that reduce the need for overnight hospital stays, enhanced recovery programmes that advocate early mobilisation, and the need for economic efficiency. Recent experience has shown that redistributing surgical procedures from the inpatient setting to ambulatory centres can be done without impacting quality. The majority of people requiring urologic surgery are now treated as day/outpatients ? thus requiring a different level of care from inpatients. Ambulatory Urology and Urogynaecology is the only book that combines urology and urogynaecology focuses on outpatient management. Packed with learning points, practical hints and tips, and boasting an international group oTable of ContentsList of Contributors xi Section I Basic Principles of an Ambulatory Service 1 1 Principles of an Ambulatory Surgery Service 3Mark Salmon and Benjamin Patel Section II Ambulatory Urogynaecology 17 2 Introduction and Epidemiology of Pelvic Floor Dysfunction 19Jay Iyer and Ajay Rane 3 Ambulatory Evaluation of Pelvic Organ Prolapse and Urinary Incontinence 33Tanvir Singh, Sandhya Gupta, and Ajay Rane 4 Role of Cystoscopy 53Arjunan Tamilselvi 5 Role of Nurse Practitioners in Ambulatory Urogynaecological Care 63Angie Rantell 6 Non-Surgical Management of Pelvic Floor Disorders 69Arjunan Tamilselvi 7 Ambulatory Surgical Procedures in Stress Urinary Incontinence 81Dudley Robinson 8 Pelvic Organ Prolapse Surgery as an Ambulatory Procedure 99Marcella Zanzarini Sanson and G. Willy Davila 9 Common Urethral and Vaginal Lesions in Ambulatory Urogynaecology 109Mugdha Kulkarni and Anna Rosamilia 10 Ambulatory Management of Childbirth Pelvic Floor Trauma 123Khaled M.K. Ismail, Rasha Kamel, and Vladimir Kalis 11 Teaching and Training in Urogynaecology 137Ajay Rane Section III Ambulatory Urology 149 Foreword 151Jordan Durrant 12 Ambulatory Penile and Inguino-Scrotal Surgery 153Ben Pullar 13 Ambulatory Management of Renal Stone Disease 159Aakash Pai 14 The Management of Recurrent Urinary Tract Infections 167Jordan Durrant 15 An Ambulatory Approach to Benign Prostatic Obstruction 175Tharani Mahesan 16 Urethral Catheters and Ambulatory Management of Urinary Retention 185Ashiv Patel 17 Paediatric Urology 193Tharani Nitkunan and Sylvia Yan 18 Urothelial Bladder Cancer: Diagnosis and Management in the Outpatient Clinic 201Jordan Durrant 19 Prostate Cancer: Diagnosis and Management in the Outpatient Clinic 207David Thurtle 20 Renal Cancer: Diagnosis and Management in the Outpatient Clinic 217Karan Wadhwa 21 Penile Cancer: Diagnosis and Management in the Outpatient Clinic 223Karen Randhawa and Hussain Alnajjar 22 Testis Cancer: Diagnosis and Management in the Outpatient Clinic 233Benjamin Patel 23 Plain X-Ray, Computed Tomography Scanning, and Nuclear Imaging in Urology 239Tharani Mahesan 24 Magnetic Resonance Imaging in Urology 247Benjamin Patel Index 251

Read more less

Book SynopsisThe derivation of structural information from spectroscopic data is now an integral part of organic chemistry courses at all Universities. Over recent years, a number of powerful two-dimensional NMR techniques (e.g. HSQC, HMBC, TOCSY, COSY and NOESY) have been developed and these have vastly expanded the amount of structural information that can be obtained by NMR spectroscopy. Improvements in NMR instrumentation now mean that 2D NMR spectra are routinely (and sometimes automatically) acquired during the identification and characterisation of organic compounds. Organic Structures from 2D NMR Spectra is a carefully chosen set of more than 60 structural problems employing 2D-NMR spectroscopy. The problems are graded to develop and consolidate a students understanding of 2D NMR spectroscopy. There are many easy problems at the beginning of the collection, to build confidence and demonstrate the basic principles from which structural information can be extracted using 2D NMR. The accompany

Read more less

Book SynopsisThe only book dedicated to this important area of urology, Ureteric Stenting comprehensively reviews the entire topic, providing highly specialized advice to enable outstanding clinical management of patients.Table of ContentsList of Contributors vii Foreword x Preface xi 1 Anatomy of the Human Ureter 1 2 Anatomic Variations of the Ureter 10 3 The Pathophysiology of Upper Tract Obstruction 16 4 Physiology of the Human Ureter 29 5 Etiology of Ureteric Obstruction 48 6 The Role of the Interventional Radiologist in Managing Ureteric Obstruction 55 7 Emergency Management of Ureteric Obstruction 67 8 The History and Evolution of Ureteral Stents 75 9 Ureteral Stent Materials: Past, Present, and Future 83 10 Physical Characteristics of Stents 91 11 Coated and Drug-Eluting Stents 102 12 Coated and Drug-Eluting Ureteric Stents 110 13 Ureteric Stents: A Perspective from the Developing World 118 14 Ethical Issues in Ureteric Stenting 130 15 Equipment and Technical Considerations During Ureteric Stenting 136 16 Extra-Anatomic Stent Urinary Bypass 149 17 Detour Extra-Anatomical Ureteric Stent 161 18 Tandem Ureteral Stents 175 19 Biodegradable Ureteric Stents 182 20 Metallic Ureteric Stents 192 21 Removal of Ureteric Stents 203 22 Encrustation of Indwelling Urinary Devices 215 23 Stent Migration 227 24 Health-Related Quality of Life and Ureteric Stents 238 25 Evidence Base for Stenting 264 26 Robotic Ureteric Reconstruction 278 27 Indwelling Ureteric Stents – Health Economics Considerations 287 28 Ureteric Stents: The Future 296 Index 298

Read more less

Book SynopsisIncluding case studies of macrocyclic marketed drugs and macrocycles in drug development, this book helps medicinal chemists deal with the synthetic and conceptual challenges of macrocycles in drug discovery efforts. Provides needed background to build a program in macrocycle drug discovery design criteria, macrocycle profiles, applications, and limitations Features chapters contributed from leading international figures involved in macrocyclic drug discovery efforts Covers design criteria, typical profile of current macrocycles, applications, and limitations Table of ContentsForeword xiii Introduction xv About the Contributors xix Part I Challenges Specific to Macrocycles 1 1 Contemporary Macrocyclization Technologies 3Serge Zaretsky and Andrei K. Yudin 1.1 Introduction 3 1.2 Challenges Inherent to the Synthesis of Macrocycles 3 1.3 Challenges in Macrocycle Characterization 6 1.4 Macrocyclization Methods 8 1.5 Cyclization on the Solid Phase 14 1.6 Summary 17 References 18 2 A Practical Guide to Structural Aspects of Macrocycles (NMR, X]Ray, and Modeling) 25David J. Craik, Quentin Kaas and Conan K. Wang 2.1 Background 25 2.2 Experimental Studies of Macrocycles 31 2.3 Molecular Modeling of Macrocyclic Peptides 38 2.4 Summary 46 Acknowledgments 47 References 47 3 Designing Orally Bioavailable Peptide and Peptoid Macrocycles 59David A. Price, Alan M. Mathiowetz and Spiros Liras 3.1 Introduction 59 3.2 Improving Peptide Plasma Half]Life 60 3.3 Absorption, Bioavailability, and Methods for Predicting Absorption 61 3.4 In Silico Modeling 70 3.5 Future Directions 71 References 72 Part II Classes of Macrocycles and Their Potential for Drug Discovery 77 4 Natural and Nature]Inspired Macrocycles: A Chemoinformatic Overview and Relevant Examples 79Ludger A. Wessjohann, Richard Bartelt and Wolfgang Brandt 4.1 Introduction to Natural Macrocycles as Drugs and Drug Leads 79 4.2 Biosynthetic Pathways, Natural Role, and Biotechnological Access 79 4.3 QSAR and Chemoinformatic Analyses of Common Features 84 4.4 Case Studies: Selected Natural Macrocycles of Special Relevance in Medicinal Chemistry 88 References 91 5 Bioactive and Membrane]Permeable Cyclic Peptide Natural Products 101Andrew T. Bockus and R. Scott Lokey 5.1 Introduction 101 5.2 Structural Motifs and Permeability of Cyclic Peptide Natural Products 101 5.3 Conformations of Passively Permeable Bioactive Cyclic Peptide Natural Products 103 5.4 Recently Discovered Bioactive Cyclic Peptide Natural Products 108 5.5 Conclusions 125 References 125 6 Chemical Approaches to Macrocycle Libraries 133Ziqing Qian, Patrick G. Dougherty and Dehua Pei 6.1 Introduction 133 6.2 Challenges Associated with Macrocyclic One]Bead]One-Compound Libraries 134 6.3 Deconvolution of Macrocyclic Libraries 134 6.4 Peptide]Encoded Macrocyclic Libraries 136 6.5 DNA] Encoded Macrocyclic Libraries 142 6.6 Parallel Synthesis of Macrocyclic Libraries 142 6.7 Diversity] Oriented Synthesis 145 6.8 Perspective 147 6.9 Conclusion 149 References 150 7 Biological and Hybrid Biological/Chemical Strategies in Diversity Generation of Peptidic Macrocycles 155Francesca Vitali and Rudi Fasan 7.1 Introduction 155 7.2 Cyclic Peptide Libraries on Phage Particles 155 7.3 Macrocyclic Peptide Libraries via In Vitro Translation 166 7.4 Emerging Strategies for the Combinatorial Synthesis of Hybrid Macrocycles In Vitro and in Cells 171 7.5 Comparative Analysis of Technologies 175 7.6 Conclusions 178 References 178 8 Macrocycles for Protein–Protein Interactions 185Eilidh Leitch and Ali Tavassoli 8.1 Introduction 185 8.2 Library Approaches to Macrocyclic PPI Inhibitors 186 8.3 Structural Mimicry 192 8.4 Multi] Cycles for PPIs 197 8.5 The Future for Targeting PPIs with Macrocycles 197 References 200 Part III The Synthetic Toolbox for Macrocycles 205 9 Synthetic Strategies for Macrocyclic Peptides 207Éric Biron, Simon Vezina]Dawod and François Bédard 9.1 Introduction to Peptide Macrocyclization 207 9.2 One Size Does Not Fit All: Factors to Consider During Synthesis Design 209 9.3 Peptide Macrocyclization in Solution 213 9.4 Peptide Macrocyclization on Solid Support 220 9.5 Peptide Macrocyclization by Disulfide Bond Formation 226 9.6 Conclusion 229 References 230 10 Ring]Closing Metathesis]Based Methods in Chemical Biology: Building a Natural Product Inspired Macrocyclic Toolbox to Tackle Protein–Protein Interactions 243Jagan Gaddam, Naveen Kumar Mallurwar, Saidulu Konda, Mahender Khatravath, Madhu Aeluri, Prasenjit Mitra and Prabhat Arya 10.1 Introduction 243 10.2 Protein– Protein Interactions: Challenges and Opportunities 243 10.3 Natural Products as Modulators of Protein–Protein Interactions 243 10.4 Introduction to Ring]Closing Metathesis 244 10.5 Selected Examples of Synthetic Macrocyclic Probes Using RCM]Based Approaches 246 10.6 Summary 259 References 259 11 The Synthesis of Peptide-Based Macrocycles by Huisgen Cycloaddition 265Ashok D. Pehere and Andrew D. Abell 11.1 Introduction 265 11.2 Dipolar Cycloaddition Reactions 266 11.3 Macrocyclic Peptidomimetics 267 11.4 Macrocyclic β]Strand Mimetics as Cysteine Protease Inhibitors 273 11.5 Conclusion 275 References 277 12 Palladium]Catalyzed Synthesis of Macrocycles 281Thomas O. Ronson, William P. Unsworth and Ian J. S. Fairlamb 12.1 Introduction 281 12.2 Stille Reaction 281 12.3 Suzuki– Miyaura Reaction 285 12.4 Heck Reaction 288 12.5 Sonogashira Reaction 290 12.6 Tsuji– Trost Reaction 293 12.7 Other Reactions 295 12.8 Conclusion 298 References 298 13 Alternative Strategies for the Construction of Macrocycles 307Jeffrey Santandrea, Anne]Catherine Bédard, Mylène de Léséleuc, Michaël Raymond and Shawn K. Collins 13.1 Introduction 307 13.2 Alternative Methods for Macrocyclization Involving Carbon–Carbon Bond Formation 307 13.3 Alternative Methods for Macrocyclization Involving Carbon–Carbon Bond Formation: Ring Expansion and Photochemical Methods 320 13.4 Alternative Methods for Macrocyclization Involving Carbon–Oxygen Bond Formation 322 13.5 Alternative Methods for Macrocyclization Involving Carbon–Nitrogen Bond Formation 327 13.6 Alternative Methods for Macrocyclization Involving Carbon–Sulfur Bond Formation 328 13.7 Conclusion and Summary 331 References 332 14 Macrocycles from Multicomponent Reactions 339Ludger A. Wessjohann, Ricardo A. W. Neves Filho, Alfredo R. Puentes and Micjel Chávez Morejón 14.1 Introduction 339 14.2 General Aspects of Multicomponent Reactions (MCRs) in Macrocycle Syntheses 344 14.3 Concluding Remarks and Future Perspectives 369 References 371 15 Synthetic Approaches Used in the Scale]Up of Macrocyclic Clinical Candidates 377Jongrock Kong 15.1 Introduction 377 15.2 Background 377 15.3 Literature Examples 378 15.4 Conclusions 406 References 406 Part IV Macrocycles in Drug Development: Case Studies 411 16 Overview of Macrocycles in Clinical Development and Clinically Used 413Silvia Stotani and Fabrizio Giordanetto 16.1 Introduction 413 16.2 Datasets Generation 413 16.3 Marketed Macrocyclic Drugs 414 16.4 Macrocycles in Clinical Studies 422 16.5 De Novo Designed Macrocycles 429 16.6 Overview and Conclusions 436 Appendix 16.A 437 16.A.1 Methods 437 References 490 17 The Discovery of Macrocyclic IAP Inhibitors for the Treatment of Cancer 501Nicholas K. Terrett 17.1 Introduction 501 17.2 DNA]Programmed Chemistry Macrocycle Libraries 502 17.3 A New Macrocycle Ring Structure 504 17.4 Design and Profiling of Bivalent Macrocycles 506 17.5 Improving the Profile of the Bivalent Macrocycles 510 17.6 Selection of the Optimal Bivalent Macrocyclic IAP Antagonist 512 17.7 Summary 515 Acknowledgments 515 References 516 18 Discovery and Pharmacokinetic–Pharmacodynamic Evaluation of an Orally Available Novel Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase and c]Ros Oncogene 1 519Shinji Yamazaki, Justine L. Lam and Ted W. Johnson 18.1 Introduction 519 18.2 Discovery and Synthesis 520 18.3 Evaluation of Pharmacokinetic Properties Including CNS Penetration 531 18.4 Evaluation of Pharmacokinetic–Pharmacodynamic (PKPD) Profiles 536 18.5 Conclusion 540 References 540 19 Optimization of a Macrocyclic Ghrelin Receptor Agonist (Part II): Development of TZP]102 545Hamid R. Hoveyda, Graeme L. Fraser, Eric Marsault, René Gagnon and Mark L. Peterson 19.1 Introduction 545 19.2 Advanced AA3 and Tether SAR 548 19.3 Structural Studies 554 19.4 Conclusions 554 Acknowledgments 555 References 556 20 Solithromycin: Fourth]Generation Macrolide Antibiotic 559David Pereira, Sara Wu, Shingai Majuru, Stephen E. Schneider and Lovy Pradeep 20.1 Introduction 559 20.2 Structure–Activity Relationship (SAR) of Ketolides and Selection of Solithromycin 559 20.3 Mechanism of Action 564 20.4 Overcoming the Ketek Effect 568 20.5 Manufacture of Solithromycin 569 20.6 Polymorphism 569 20.7 Pharmaceutical Development 569 20.8 Clinical Data 574 20.9 Summary 574 References 574 Index 579

Read more less

Book SynopsisA comprehensive and practical resource for analyses of crossover designs For ethical reasons, it isvital to keep the number of patients in a clinical trial aslow as possible.As evidenced by extensive research publications, crossover designcan bea useful and powerfultool to reduce the number of patients needed for a parallel group design in studying treatmentsfor non-curable chronic diseases. This book introduces commonly-used and well-established statistical tests and estimators in epidemiology that can easily be applied to hypothesis testing and estimation of the relative treatment effect for various types of data scale in crossover designs. Models with distribution-free random effects are assumed and hence most approaches considered here are semi-parametric. The book provides clinicians and biostatisticians with the exact test procedures and exact interval estimators, which are applicable even when the number of patients in a crossover trial is small. SystematTable of ContentsAbout the author xi Preface xii About the companion website xiv 1 Crossover design – definitions, notes, and limitations 1 1.1 Unsuitability for acute or most infectious diseases 2 1.2 Inappropriateness for treatments with long-lasting effects 2 1.3 Loss of efficiency in the presence of carry-over effects 3 1.4 Concerns of treatment-by-period interaction 3 1.5 Flaw of the commonly used two-stage test procedure 4 1.6 Higher risk of dropping out or being lost to follow-up 4 1.7 More assumptions needed in use of a crossover design 5 1.8 General principle and conditional approach used in the book 5 2 AB/BA design in continuous data 7 2.1 Testing non-equality of treatments 10 2.2 Testing non-inferiority of an experimental treatment to an active control treatment 11 2.3 Testing equivalence between an experimental treatment and an active control treatment 12 2.4 Interval estimation of the mean difference 13 2.5 Sample size determination 16 2.5.1 Sample size for testing non-equality 16 2.5.2 Sample size for testing non-inferiority 17 2.5.3 Sample size for testing equivalence 18 2.6 Hypothesis testing and estimation for the period effect 19 2.7 Estimation of the relative treatment effect in the presence of differential carry-over effects 21 2.8 Examples of SAS programs and results 22 Exercises 27 3 AB/BA design in dichotomous data 30 3.1 Testing non-equality of treatments 34 3.2 Testing non-inferiority of an experimental treatment to an active control treatment 36 3.3 Testing equivalence between an experimental treatment and an active control treatment 39 3.4 Interval estimation of the odds ratio 40 3.5 Sample size determination 42 3.5.1 Sample size for testing non-equality 42 3.5.2 Sample size for testing non-inferiority 42 3.5.3 Sample size for testing equivalence 43 3.6 Hypothesis testing and estimation for the period effect 45 3.7 Testing and estimation for carry-over effects 47 3.8 SAS program codes and likelihood-based approach 48 Exercises 51 4 AB/BA design in ordinal data 57 4.1 Testing non-equality of treatments 62 4.2 Testing non-inferiority of an experimental treatment to an active control treatment 64 4.3 Testing equivalence between an experimental treatment and an active control treatment 65 4.4 Interval estimation of the generalized odds ratio 66 4.5 Sample size determination 67 4.5.1 Sample size for testing non-equality 67 4.5.2 Sample size for testing non-inferiority 68 4.5.3 Sample size for testing equivalence 68 4.6 Hypothesis testing and estimation for the period effect 70 4.7 SAS codes for the proportional odds model with normal random effects 72 Exercises 74 5 AB/BA design in frequency data 75 5.1 Testing non-equality of treatments 78 5.2 Testing non-inferiority of an experimental treatment to an active control treatment 81 5.3 Testing equivalence between an experimental treatment and an active control treatment 83 5.4 Interval estimation of the ratio of mean frequencies 84 5.5 Sample size determination 86 5.5.1 Sample size for testing non-equality 86 5.5.2 Sample size for testing non-inferiority 87 5.5.3 Sample size for testing equivalence 88 5.6 Hypothesis testing and estimation for the period effect 88 5.7 Estimation of the relative treatment effect in the presence of differential carry-over effects 90 Exercises 92 6 Three-treatment three-period crossover design in continuous data 95 6.1 Testing non-equality between treatments and placebo 102 6.2 Testing non-inferiority of an experimental treatment to an active control treatment 103 6.3 Testing equivalence between an experimental treatment and an active control treatment 104 6.4 Interval estimation of the mean difference 104 6.5 Hypothesis testing and estimation for period effects 105 6.6 Procedures for testing treatment-by-period interactions 107 6.7 SAS program codes and results for constant variance 109 Exercises 111 7 Three-treatment three-period crossover design in dichotomous data 115 7.1 Testing non-equality of treatments 121 7.1.1 Asymptotic test procedures 121 7.1.2 Exact test procedures 123 7.1.3 Procedures for simultaneously testing non-equality of two experimental treatments versus a placebo 124 7.2 Testing non-inferiority of an experimental treatment to an active control treatment 126 7.3 Testing equivalence between an experimental treatment and an active control treatment 127 7.4 Interval estimation of the odds ratio 129 7.5 Hypothesis testing and estimation for period effects 131 7.6 Procedures for testing treatment-by-period interactions 133 7.7 SAS program codes and results for a logistic regression model with normal random effects 136 Exercises 138 8 Three-treatment three-period crossover design in ordinal data 141 8.1 Testing non-equality of treatments 150 8.1.1 Asymptotic test procedures 150 8.1.2 Exact test procedure 152 8.2 Testing non-inferiority of an experimental treatment to an active control treatment 153 8.3 Testing equivalence between an experimental treatment and an active control treatment 153 8.4 Interval estimation of the GOR 154 8.5 Hypothesis testing and estimation for period effects 156 8.6 Procedures for testing treatment-by-period interactions 159 8.7 SAS program codes and results for the proportional odds model with normal random effects 160 Exercises 162 9 Three-treatment three-period crossover design in frequency data 164 9.1 Testing non-equality between treatments and placebo 170 9.2 Testing non-inferiority of an experimental treatment to an active control treatment 173 9.3 Testing equivalence between an experimental treatment and an active control treatment 174 9.4 Interval estimation of the ratio of mean frequencies 175 9.5 Hypothesis testing and estimation for period effects 178 9.6 Procedures for testing treatment-by-period interactions 179 Exercises 181 10 Three-treatment (incomplete block) crossover design in continuous and dichotomous data 183 10.1 Continuous data 185 10.1.1 Testing non-equality of treatments 188 10.1.2 Testing non-equality between experimental treatments (or non-nullity of dose effects) 189 10.1.3 Interval estimation of the mean difference 190 10.1.4 SAS codes for fixed effects and mixed effects models 192 10.2 Dichotomous data 194 10.2.1 Testing non-equality of treatments 197 10.2.2 Testing non-equality between experimental treatments (or non-nullity of dose effects) 199 10.2.3 Testing non-inferiority of either experimental treatment to an active control treatment 199 10.2.4 Interval estimation of the odds ratio 200 10.2.5 SAS codes for the likelihood-based approach 202 Exercises 203 References 208 Index 216

Read more less

Book SynopsisThe Mount Sinai Expert Guides provide quick access to point-of-care specialist clinical information for physicians across a range of therapeutic areas. For each specialty area, the guides emphasize: Common pitfalls in diagnosis and management How to prevent complications Diagnostic and treatment algorithms Key scientific trials Evidence-based clinical content Major society guidelines in order to summarize the very latest in diagnosis and management of diseases and related symptoms. Edited by renowned specialists from the Icahn School of Medicine at Mount Sinai, key faculty members provide the content for all chapters. To ensure consistency within each book and the series as a whole, chapters follow a unified structure throughout. Bonus features such as online case studies with related questions for self-assessment, key patient advice, andICD codes are provided via the series companion website.Table of ContentsContributors ix Series Foreword xvii Preface xviii List of Abbreviations xix About the Companion Website xxviii Part 1: Oncology 1 Breast Cancer 3Jeanette Guziel and Charles L. Shapiro 2 Prostate Cancer 23Reza Mehrazin and William K. Oh 3 Bladder Cancer 32Matthew D. Galsky 4 Renal Cancer 43Bobby C. Liaw, Reza Mehrazin, and Che-Kai Tsao 5 Testicular Cancer 56Aditya V. Shreenivas and Seth M. Cohen 6 Lung Cancer 66Rajwanth Veluswamy and Jorge E. Gomez 7 Malignant Mesothelioma 79Nicholas C. Rohs and Zishuo I. Hu 8 Liver Cancer 89Augusto Villanueva, Myron E. Schwartz, and Josep M. Llovet 9 Gallbladder/Biliary Duct Cancers 101Rajwanth Veluswamy, Anuja Kriplani, and Celina Ang 10 Pancreas Cancer 111Max W. Sung 11 Colorectal Cancer 118Kenneth L. Angelino, Jason W. Steinberg, and Peter S. Kozuch 12 Gastric Cancer 131Sofya Pintova 13 Esophageal Cancer 139Madhuri Rao and Andrea S. Wolf 14 Anal Cancer 153Ashley J. D’Silva, Danielle S. Seiden, and Peter S. Kozuch 15 Invasive Epithelial Ovarian Cancer 166Brittney S. Zimmerman, Jeanette Guziel, and Amy Tiersten 16 Endometrial Cancer 181Jamal Rahaman and Carmel J. Cohen 17 Cervical Cancer 194Navya Nair, Ann Marie Beddoe, and Peter Dottino 18 Melanoma 204Philip Friedlander and Corazon B. Cajulis 19 Sarcomas 214Robert G. Maki 20 Thyroid Cancer 221Aaron M. Etra and Krzysztof Misiukiewicz 21 Head and Neck Cancer 230Le Min Lee and Bruce E. Culliney 22 Brain Tumors 241Rebecca M. Brown and Ad´ılia Hormigo 23 Neuroendocrine Tumors 255Richard R.P. Warner, Jacob A. Martin, and Michelle K. Kim Part 2: Malignant Hematology 24 Myeloproliferative Neoplasms 271Sangeetha Venugopal, Daniel Aruch, and John Mascarenhas 25 Myelodysplastic Syndromes 288Thomas U. Marron and Lewis R. Silverman 26 Multiple Myeloma and Plasma Cell Disorders 298Siyang Leng and Ajai Chari 27 Acute Myeloid Leukemia 308Kevin Barley and Shyamala C. Navada 28 Acute Lymphoblastic Leukemia 319Jaclyn C. Davis and Birte Wistinghausen 29 Chronic Lymphocytic Leukemia 332Adam F. Binder and Janice L. Gabrilove 30 Non-Hodgkin Lymphoma 342Adam F. Binder and Joshua D. Brody 31 Hodgkin Lymphoma 354Jonah Shulman, Parth R. Rao, and Akshay Sudhindra 32 Primary Central Nervous System Lymphoma 364Rebecca M. Brown and Ad´ılia Hormigo Part 3: BONE MARROW TRANSPLANT 33 Autologous Stem Cell Transplantation for Plasma Cell Disorders 379Keren Osman 34 Allogeneic Stem Cell Transplantation Overview 385Parth R. Rao, Amir Steinberg, and Luis Isola 35 Allogeneic Stem Cell Transplantation for AML and MDS 392Alla Keyzner 36 Stem Cell Transplantation for Lymphoproliferative Disorders 400Doyun Park, Eileen Scigliano, and Amir Steinberg 37 Infectious Complications of Stem Cell Transplantation 404Meenakshi M. Rana and Amir Steinberg 38 Acute Graft Versus Host Disease 412Anne S. Renteria, James L.M. Ferrara, and John E. Levine Part 4: Multidisciplinary Care of Cancer Patients 39 Oncologic Emergencies 423Scot A. Niglio and Adriana K. Malone 40 Thrombosis in Cancer Patients 435Doyun Park, Caroline Cromwell, Mala Varma, and Ilan Shapira 41 Imaging of Cancer Patients 447Idoia Corcuera-Solano, Mathilde Wagner, and Bachir Taouli 42 Overview of Radiation Oncology 454Ronald D. Ennis 43 Orthopedic Oncology 463Meredith K. Bartelstein and Ilya Iofin 44 Ophthalmologic Oncology 473Albert Y. Wu and Kalla A. Gervasio 45 Cardio-Oncology 486Gagan Sahni 46 Psychiatric and Psychologic Dimensions of Cancer Care 501Talia Wiesel 47 Geriatric Oncology 514Ali John Zarrabi, Ran Huo, and Cardinale B. Smith 48 Palliative Care 519Lori Spoozak and Bethann Scarborough 49 Nutrition and Symptom Management 528Paula Occiano, Melissa Nagelberg, and Raquela Adelsberg 50 Cancer Survivorship 535Lindsay Haines and Charles L. Shapiro 51 Pediatric Cancer: Solid Tumors and Lymphoma 543Surabhi Batra and Birte Wistinghausen 52 Pediatric Cancer: Brain Tumors 556Surabhi Batra and Birte Wistinghausen Index 566

Read more less

Book SynopsisProbiotic Dairy Products, 2nd Edition The updated guide to the most current research and developments in probiotic dairy products The thoroughly revised and updated second edition ofProbiotic Dairy Productsreviews the recent advancements in the dairy industry and includes the latest scientific developments in regard to the ''functional'' aspects of dairy and fermented milk products and their ingredients. Since the publication of the first edition of this text, there have been incredible advances in the knowledge and understanding of the human microbiota, mainly due to the development and use of new molecular analysis techniques. This new edition includes information on the newest developments in the field. It offers information on the new omic' technologies that have been used to detect and analyse all the genes, proteins and metabolites of individuals' gut microbiota. The text also includes a description of the history of probiotics and explores tTable of ContentsList of Contributors xi Preface to the Technical Series, Second Edition xv Preface to the Technical Series, First Edition xvii Preface to the Second Edition xix Preface to the First Edition xxi 1 Microbiota of the Human Gut 1H.B. Ghoddusi and L.V. Thomas 1.1 Background 1 1.2 The human GI tract and its microbiota 2 1.3 Functions of the GI microbiota 5 1.4 Influences on the GI tract and its microbiota 7 1.5 Conclusions 9 References 10 2 Probiotics: The First 10 000 Years 17R. Levin 2.1 In the beginning 17 2.2 The intervention of science 19 2.3 A remarkable sequence of important discoveries 20 2.4 Could disinfection be the solution? 21 2.5 On the cusp of a major breakthrough 22 2.6 The urge for progress switches to the USA (1914–1931) 25 2.7 Meanwhile, in Europe 28 2.8 The ultimate breakthrough comes from Japan? 29 2.9 Conclusions 32 Acknowledgements 33 References 33 3 Genomic Characterisation of Starter Cultures and Probiotic Bacteria 37G.E. Felis, S. Torriani, A.B. Florez and B. Mayo 3.1 Introduction 37 3.2 Genome sequencing and comparative genomics: insights into evolution and adaptation to dairy environments 40 3.2.1 Phylum Firmicutes 41 3.2.2 Phylum Actinobacteria 45 3.2.3 Other micro]organisms 46 3.3 Application of genome analysis to LAB and bifidobacteria 47 3.3.1 In silico safety assessment of LAB bifidobacteria 47 3.3.2 Unravelling LAB and bifidobacteria properties 51 3.4 Concluding remarks 56 References 57 4 Production and Maintaining Viability of Probiotic Micro]organisms in Dairy Products 67A.Y. Tamime, M. Saarela, M. Wszolek, H. Ghoddousi, D.M. Linares and N.P. Shah 4.1 Introduction 67 4.2 Probiotic micro]organisms 68 4.2.1 General characteristics 68 4.2.2 Examples of commercial starter culture blends 69 4.3 Economic value 72 4.4 Unfermented probiotic milk 72 4.5 Probiotic fermented milks and beverages 75 4.5.1 Lactic acid fermentations 76 4.5.2 Yeast–lactic acid fermentations 90 4.5.3 Mould–lactic acid fermentations 93 4.5.4 Quality appraisal of probiotic fermented milks 93 4.6 Probiotic cheeses 95 4.6.1 Methods of introduction of probiotics in cheese 95 4.6.2 Probiotic strain selection for cheesemaking 96 4.6.3 Very hard and hard cheese varieties 99 4.6.4 Semi]hard varieties 102 4.6.5 Brined cheeses 103 4.6.6 Soft cheeses 105 4.6.7 Pasta Filata cheeses 108 4.6.8 Miscellaneous cheeses 108 4.7 Probiotic ice cream, frozen desserts and frozen yoghurt 111 4.7.1 Background 111 4.7.2 Ice-cream 111 4.8 Dried probiotic dairy products 112 4.8.1 Introduction 112 4.8.2 Infant formula 113 4.8.3 Dairy]based dried products 114 4.9 Miscellaneous probiotic dairy products 115 4.9.1 Fat]based products 115 4.9.2 Long shelf]life fermented milk drinks or beverages 115 4.9.3 Milk] and water]based cereal puddings 116 4.9.4 Mousses, desserts and spreads 116 4.10 Viability of probiotic micro]organisms 117 4.10.1 Composition of the fermentation medium 118 4.10.2 Viability as affected by oxygen 119 4.11 Approaches to improve the viability of the probiotic micro]organisms in the product 120 4.11.1 Selection of bacterial strain(s) 120 4.11.2 Type of packaging container 120 4.11.3 Rate of inoculation 121 4.11.4 Two]stage fermentation 121 4.11.5 Microencapsulation technique 122 4.11.6 Supplementation of the milk with nutrients 122 4.11.7 The use of oxygen scavengers 124 4.11.8 The addition of cysteine 124 4.12 Future developments and overall conclusions 125 Acknowledgement 126 References 126 5 Current Legislation of Probiotic Products 165M. Hickey 5.1 Introduction and background 165 5.2 The situation in Japan 168 5.2.1 Subsystems of FOSHU 170 5.2.2 Essential elements for obtaining FOSHU approval 172 5.2.3 Features of the new category of foods with function claims 175 5.2.4 Unique features of the Japanese FOSHU system 176 5.3 The legislative situation in the European Union 176 5.3.1 Relevant EU food safety legislation 176 5.3.2 Novel food regulation in the European Union 177 5.3.3 Genetically modified organisms 178 5.3.4 EU food]labelling provisions 178 5.3.5 EU nutrition and health claims 178 5.3.6 Types of health claims 179 5.4 The USA’s legislative situation on probiotics and related health claims 183 5.4.1 Claims and labelling in the USA 184 5.4.2 The role of the Federal Trade Commission (FTC) and legal challenges 187 5.5 The Canadian legislative situation regarding health claims and functional foods 189 5.5.1 Background 189 5.5.2 Health claims on foods in Canada 189 5.5.3 Probiotic claims 190 5.6 Health foods and functional foods in China 191 5.6.1 Introduction 191 5.6.2 Chinese legislative structures 192 5.6.3 The healthy (functional) foods sector in China and its regulation 192 5.6.4 Types of health claims in China and their approval 194 5.6.5 China’s probiotic market size and potential 194 5.7 Codex Alimentarius Commission (CAC) 196 5.7.1 Background 196 5.7.2 Acceptance of Codex standards and their role in the World Trade Organisation (WTO) 197 5.7.3 Codex and food]labelling claims 198 5.7.4 Codex standard for fermented milks 200 5.8 Some conclusions and possible future legislative prospects for probiotics 201 Acknowledgements 202 References 202 6 Enumeration and Identification of Mixed Probiotic and Lactic Acid Bacteria Starter Cultures 207A.Č. Majhenic,̌ P.M. Lorbeg and P. Treven 6.1 Introduction 207 6.2 Classification 207 6.3 Phenotypic methods 208 6.3.1 Differential plating 208 6.3.2 Carbohydrate fermentation]based methods 211 6.3.3 Spectroscopic methods 213 6.3.4 Fluorescence dyes]based methods 216 6.4 Genetic methods 219 6.4.1 Polymerase chain reaction-based methods 219 6.4.2 DNA banding pattern]based methods 224 6.4.3 DNA sequencing]based methods 230 6.4.4 Probe hybridisation methods 235 6.5 Conclusions 237 References 238 7 Prebiotic Ingredients in Probiotic Dairy Products 253X. Wang and R.A. Rastall 7.1 Introduction 253 7.2 Criteria for an ingredient to be classified as a prebiotic 254 7.3 Health benefits of prebiotics and their mechanisms of action 254 7.3.1 Short]chain fatty acids and human metabolism 255 7.3.2 Mineral absorption 256 7.3.3 Energy intake and appetite regulation 256 7.3.4 Lipid metabolism 258 7.3.5 Immune function modulation of prebiotics 258 7.3.6 Colorectal cancer risk and prebiotics 259 7.3.7 Gut permeability 260 7.3.8 Colon motility and faecal bulking with application to constipation 261 7.4 Inulin]type fructans as prebiotics 261 7.4.1 Determination of inulin]type fructans 262 7.4.2 Production of inulin]type fructans 264 7.4.3 Physical and chemical characteristics of inulin]type fructans and application in the food industry 264 7.4.4 Prebiotic effects of inulin]type fructans 265 7.4.5 Health benefits of inulin]type fructans 265 7.5 Galactooligosaccharides as prebiotics 267 7.5.1 Production and determination of galactooligosaccharides 269 7.5.2 Application of galactooligosaccharides in the food industry 269 7.5.3 The prebiotic effect of galactooligosaccharides 269 7.5.4 Infant nutrition and galactooligosaccharides 271 7.5.5 Health benefit of galactooligosaccharides 272 7.6 Resistant starch and other glucose]based non]digestible carbohydrates 276 7.7 Xylooligosaccharides 279 7.8 Other potential prebiotics candidates and summary 279 References 279 8 An Overview of Probiotic Research: Human and Mechanistic Studies 293G. Zoumpopoulou, E. Tsakalidou and L.V. Thomas 8.1 Mechanisms underlying probiotic effects 293 8.1.1 Probiotic effects on the gut microbiota and its metabolites 294 8.1.2 Probiotic immune modulation 295 8.1.3 Probiotic effects on gut barrier function 296 8.1.4 Probiotics and the gut–brain axis 296 8.1.5 Probiotic mechanisms in the urogenital tract 297 8.1.6 Survival of the gut microbiota through the gut 297 8.2 Probiotic human studies: gastrointestinal conditions 297 8.2.1 Inflammatory bowel disease (IBD) 297 8.2.2 Irritable bowel syndrome (IBS) 302 8.2.3 Constipation 303 8.2.4 Diarrhoeal diseases 304 8.2.5 Paediatric conditions 306 8.3 Probiotic research: human studies investigating extra]intestinal conditions 308 8.3.1 Common infectious diseases 309 8.3.2 Allergic diseases 310 8.3.3 Urogenital conditions 313 8.3.4 Obesity]related disease 314 8.3.5 Liver disease 317 8.3.6 Cancer 318 8.3.7 Immune disorders: HIV 319 8.3.8 Trials investigating aspects of the gut–brain axis 320 8.4 Conclusions 321 References 321 9 Production of Vitamins, Exopolysaccharides and Bacteriocins by Probiotic Bacteria 359D.M. Linares, G. Fitzgerald, C. Hill, C. Stanton and P. Ross 9.1 Introduction 359 9.2 Vitamin production by probiotic bacteria 359 9.2.1 Background 359 9.2.2 Folate 360 9.2.3 Vitamin B12 362 9.2.4 Riboflavin and thiamine 363 9.2.5 Vitamin K 364 9.3 Exopolysaccharides (EPS) production by probiotic bacteria 364 9.3.1 Introduction 364 9.3.2 Classification of exopolysaccharides 365 9.3.3 Health benefits of exopolysaccharides 365 9.4 Production of bacteriocins by probiotic cultures 368 9.4.1 Background 368 9.4.2 Production of antimicrobials as a probiotic trait 369 9.4.3 Classification of bacteriocins 369 9.4.4 Antimicrobial potential of Lactobacillus spp. 372 9.4.5 Antimicrobial potential of Bifidobacterium spp. 375 9.4.6 Other lactic acid bacteria species with antimicrobial potential 376 9.5 Overall conclusions 376 Acknowledgements 377 References 377 10 Future Development of Probiotic Dairy Products 389M. Saarela 10.1 Developments in the probiotic field in the European Union (EU) 389 10.2 The current probiotic market and its trends 391 10.3 Recent developments in the probiotic research 392 10.4 Future target areas for research and conclusion 393 References 393 Index 395

Read more less

Book SynopsisClinical communication underpins safe patient care. The effective health professional sees illness through the patient's eyes and understands what matters most to him or her. Effectiveness means gathering hard clinical data about the physical changes affecting the patient, understanding why the patient is concerned, conveying this to other health care professionals and involving the patient at every stage of management decisions. The evidence for good clinical communication is well established, although there are challenges. While listening is the basis of sound diagnosis and clinical reasoning, its absence affects patient outcomes particularly when patients are not permitted to make their concerns known or when there are gaps in information flow or communication between the professionals caring for them. The ABC of Clinical Communication considers the evidence pertinent to individual encounters between patients and their health professionals, how to achieve efficient flow of infTable of ContentsPreface, vii Contributors, ix 1 Why Clinical Communication Matters, 1John Frain 2 The Consultation, 7Jonathan Silverman 3 Communication and Personality Type, 13Gillian B. Clack 4 Shared Decision-Making, 19John Frain and Andy Wearn 5 Communication in Clinical Teams, 29Alison Cracknell and Nicola Cooper 6 Communication in Medical Records, 35Nigel D.C. Sturrock 7 Advanced Communication for Specific Situations, 41Nivedita Aswani, Vanessa Cox and Julia Surridge 8 Communication and Mental Health, 49Lee Smith 9 Communication at the End of Life, 55Adam Walczak, Phyllis Butow and Josephine Clayton 10 Teaching Clinical Communication, 61John Frain and Magdy Abdalla Recommended Books, Articles and Websites, 69 Index, 71

Read more less

Book SynopsisThis book offers a detailed, practical guide to incorporating minimally invasive cosmetic surgery into dental practice. Chapters thoroughly examine all aspects of using these materials in practice, and present step-by-step techniques for injecting and placing neurotoxins and fillers, with specific recommendations for product selection and in-depth information on case management. Anatomical drawings and clinical photographs depict the procedures and concepts described. From patient evaluation, treatment planning, and product selection to techniques, managing complications, and marketing the service, Neurotoxins and Fillers in Facial Esthetic Surgery provides a complete resource for using these techniques in practice. Coverage encompasses facial anatomy, neurotoxins, cosmetic fillers, hyaluronic acid dermal fillers, Radiesse calcium hydroxylapatite injectable filler, pearls and pitfalls, and how to build your practice. Offers a complete but easy-to-use-reference on all aspects of how to Table of ContentsList of Contributors xi Foreword xiii About the Companion Website xv 1 Facial Anatomy and Patient Evaluation 1Timothy Osborn and Bradford M. Towne 1.1 Facial Anatomy 1 1.2 Anatomy of Facial Skin 1 1.3 Anatomy of the Superficial Fat Compartments 2 1.4 Anatomy of the Facial Fasciae 3 1.5 Anatomy of the Facial Mimetic Muscles 5 1.6 Anatomy of the Deep Facial Fat Compartments 7 1.7 Anatomy of the Ligamentous Structures (Retaining Ligaments) of the Face 8 1.8 The Blood Supply of the Face 10 1.9 The Aging Face 10 1.10 Patient Selection, Assessment, Records 13 1.11 Patient Selection and Assessment 14 1.12 Treatment Sequencing 15 References 2 Neurotoxins: The Cosmetic Use of Botulinum Toxin A 19Jon D. Perenack and Shelly Williamson‐Esnard 2.1 Botulinum Neurotoxins Introduction 19 2.2 Botulinum Toxins Physiology and Characteristics 20 2.3 Manufacturing Process 20 2.4 Clinical Usage 24 2.4.1 Age of Patient Treated 25 2.4.2 Storage and Preparation of BoNTA 26 2.4.3 Patient Preparation and General Injection Tips 28 2.4.4 Treatment Recommendations for Specific Areas 30 2.4.4.1 Glabella 30 2.4.4.2 Forehead 32 2.4.4.3 Crow’s Feet – Lateral Orbital Lines 32 2.4.4.4 Indirect Browlift 35 2.4.4.5 Correcting Brow Asymmetry 35 2.4.4.6 Other Midface Techniques: Bunny Lines 36 2.4.4.7 Perioral Modifications with BoNTA 36 2.4.4.8 Treatment of Platysmal Bands 39 2.5 Treating Facial Asymmetries Secondary to Muscle Paralysis 41 2.6 Post‐ treatment Recommendations and Complications 41 2.7 Conclusion 42 References 43 3 Cosmetic Fillers 47Alexandra Radu and Faisal A. Quereshy 3.1 History of Cosmetic Fillers 47 3.1.1 Emergence of Autologous Fillers 48 3.1.2 Emergence of Non‐autologous Fillers 48 3.1.2.1 Silicones 49 3.1.2.2 Bovine Collagen 49 3.1.2.3 Porcine Collagen 49 3.1.2.4 Polymethylmethacrylate (PMMA) 49 3.1.2.5 Hyaluronic Acid 50 3.1.2.6 Dextran Beads in Hyaluronic Acid 50 3.1.2.7 Poly‐l‐lactic Acid 50 3.1.2.8 Calcium Hydroxylapatite 50 3.1.2.9 Polyvinyl Microspheres Suspended in Polyacrylamide 51 3.1.2.10 Polytetrafluoroethylene (PTFE) 51 3.1.2.11 Polyoxyethylene and Polyoxypropylene 51 3.2 Classification 51 3.2.1 Biodegradable Facial Fillers 51 3.2.2 Autologous and Allogeneic Facial Fillers 51 3.2.3 Xenograft Facial Fillers 53 3.2.4 Synthetic Facial Fillers 53 3.2.5 Nonbiodegradable Facial Fillers 53 3.3 Ease of Use 53 3.4 Benefits 55 3.5 Complications 58 References 61 4 Hyaluronic Acid Dermal Fillers 63Tirbod Fattahi and Salam Salman 4.1 Introduction 63 4.2 Hyaluronic Acid 63 4.3 Available Products 64 4.4 Clinical Indications 64 4.5 Injection Techniques 64 4.6 Selection Process 65 4.7 Reversibility of HA Fillers 65 4.8 Clinical Scenarios 66 4.8.1 Nasolabial Grooves 66 4.8.2 Lips 66 4.8.3 Tear Troughs 66 4.8.4 Glabella 67 4.9 Post‐ Injection Instructions 68 4.10 Longevity of HA Fillers 68 4.11 Conclusion 69 References 69 5 Radiesse™ Calcium Hydroxylapatite Injectable Filler 71Nikita Gupta, Onir L. Spiegel, and Jeffrey H. Spiegel 5.1 Treatment in Practice 72 References 74 6 Pearls and Pitfalls of Neurotoxins and Facial Fillers 75Raffi Der Sarkissian 6.1 Pearls and Pitfalls in Neurotoxin Use 75 6.2 Neurotoxin Preparation and Storage 75 6.3 Choice of Syringes and Needles 76 6.4 Basic Injection Principles 77 6.5 Specific Injection Pearls Based on Injection Site 78 6.5.1 Glabellar Techniques 78 6.5.2 Forehead Techniques 80 6.5.3 Periorbital Techniques 81 6.5.4 Treatment of Bunny Lines 83 6.5.5 Depressor Anguli Oris Techniques 83 6.5.6 Perioral Techniques 83 6.5.7 Levator Labii Superioris alaeque Nasi 84 6.5.8 Techniques for Chin Dimpling 85 6.5.9 Treatment of Platysmal Bands 85 6.5.10 Treatment for Masseter Hypertrophy 86 6.6 Neurotoxin Complications 87 6.7 Cosmetic Facial Fillers: Pearls and Pitfalls 88 6.8 Technical Pearls 91 6.9 Needles vs. Cannulas 92 6.10 Specific Injection Pearls 92 6.10.1 Fine Lines 92 6.10.2 Melolabial Groove 92 6.10.3 Labiomandibular Groove 93 6.10.4 Pre Jowl Sulcus 93 6.10.5 Labiomental Groove 93 6.10.6 Midface Volumization 94 6.10.7 Temporal Hollows 96 6.10.8 Lips 97 6.10.9 Nasojugal Groove 97 6.11 Complications of Facial Fillers 99 6.11.1 Bruising 99 6.11.2 Nodules 99 6.11.3 Overcorrection 99 6.11.4 Tyndall Effect 100 6.11.5 Calcium Hydroxylapatite 100 6.11.6 Sculptra 100 6.11.7 Granuloma Formation 100 6.11.8 Vascular Compromise 100 References 102 7 Building Your Practice 103Jay R. Levine 7.1 Internet Marketing: What’s in it for you? 103 7.2 Promoting Your Practice: Formulating a Strategy 103 7.3 Website Design Companies 104 7.4 Building Your Brand 104 7.5 Print Marketing 104 7.6 Website Design: Choosing a Designer 104 7.6.1 Other Items to Consider when Choosing a Website Designer 105 7.6.2 Designing Your Website 106 7.6.2.1 Connect with the User 106 7.6.2.2 Outside Perspective 106 7.6.2.3 Accuracy 106 7.6.2.4 Doctor Bios – How Important Are They? 106 7.6.2.5 Accessibility 106 7.6.2.6 Additional Features 107 7.6.3 SEO: More on Search Engines 107 7.6.3.1 Five Basic SEO Steps you can Take Yourself 107 7.6.3.2 Blogging 108 7.6.3.3 SEO: When to Call in the Experts 108 7.6.4 Online Ads: PPC with Google AdWords 108 7.6.4.1 Managing AdWords 108 7.6.5 Social Media: Getting Started 108 7.6.5.1 The Three Es of Social Marketing 108 7.6.5.2 How to Gain Followers 109 7.6.5.3 Facebook 109 7.6.5.4 Instagram 109 7.6.5.5 Twitter 109 7.6.5.6 YouTube 109 7.6.5.7 Pinterest 110 7.6.5.8 LinkedIn 110 7.7 Protecting Your Practice Online 110 7.8 Internet Marketing: Measuring Your Progress 110 7.9 Marketing Is Communication 110 References 111 Index 113

Read more less

Book SynopsisThe conceptualization and formulation of skin care products intended for topical use is a multifaceted and evolving area of science. Formulators must account for myriad skin types, emerging opportunities for product development as well as a very temperamental retail market. Originally published as Apply Topically in 2013 (now out of print), this reissued detailed and comprehensive handbook offers a practical approach to the formulation chemist''s day-to-day endeavors by: Addressing the innumerable challenges facing the chemist both in design and at the bench, such as formulating with/for specific properties; formulation, processing and production techniques; sensory and elegancy; stability and preservation; color cosmetics; sunscreens; Offering valuable guidance to troubleshooting issues regarding ingredient selection and interaction, regulatory concerns that must be addressed early in development, and the extrapolation of preservative systems, fragranceTable of ContentsPreface ix Section I Preliminary Considerations and Selection of Raw Materials 1 Pre-formulation Design and Considerations 3 Howard Epstein 2 The Use of Thickeners in Topically Applied Formulations 29 Jed Riemer and Tom Russo 3 The Incorporation of Delivery Systems into Topical Formulations: A Case Study on the Use of Salicylic Acid for Acne Treatment 45 Nripen S. Sharma, Bryan Grossman and Sam Shefer 4 Formulating Skin Care Products with Silicones: Approaches and Strategies 59 Bartley Maxon and Michael Starch 5 The Use of Corn-derived Ingredients in Personal Care Applications 115 Cindy Yu Section II Formulation, Processing and Production Techniques 6 Emulsions and their Characterization by Texture Profile Analysis 131 Roger L. McMullen, Mihaela Gorcea and Susan Chen 7 High Internal Phase Water-in-oil Emulsions 155 Paul Thau Introduction 155 8 Manufacturing Topical Formulations: Scale-up from Lab to Pilot Production 167 Michael Kimball 9 Foam: A Unique Delivery Vehicle for Topically Applied Formulations 233 Dov Tamarkin Section III Testing and Measurements Methods 10 Using Experimental Design to Optimize Formulations 263 Joseph Albanese 11 Rheological Properties of Topical Formulations 287 Hemi Nae 12 Viscosity Measurement for Topically Applied Formulations 346 Daphne Benderly 13 Fourier Transform Infrared (FTIR) Spectroscopic Imaging Analysis of Topical Formulations 369 Samuel Gourion-Arsiquaud, Joel Coret, and David J. Moore Section IV Sensory and Elegancy 14 Creating Appealing Topically Applied Formulations: Linking Physical Aspects to Marketing Psychology 381 J. Mark Chandler 15 The Use of Fragrance in Topically Applied Formulations 397 Steve Herman Section V Stability and Preservation 16 Stability Testing for Topical Formulation Development 427 Gary R. Kelm 17 Preservation of Topical Formulations: An Historical and Practical Overview 463 Slawomir Paul Cebulski 18 Microbiological Stability for Skin Care Formulations 485 Kausar Malik Section VI Color Cosmetics 19 Lip Care Product Formulation Strategies 513 Daniel Sango and David Binder 20 Formulation of Nail Care Products 539 Robert W. Sandewicz Section VII Sunscreens 21 Formulation of Sunscreens in the United States Patricia Aikens 22 Formulating a Day Cream with SPF: A Case Study 611 Anne Pouillot and Rachel Ametsitsi Glossary of Terms, by Chapter 635 Author Biographies 655 Index 661

Read more less

Book SynopsisCompiles the most current information on the Zika virus and its associated diseases This comprehensive book provides the most up-to-date information for students, medical students, and scientists on Zika virus and its associated diseases. It includes all the information related to the Zika virus since its discovery in 1947; its epidemic outbreak in 2007-2014; how the epidemiology changed in America in 2015-2016; its mode of transmission; how to prevent and treat it; and associated diseases. Zika Virus and Diseases: From Molecular Biology to Epidemiology offers complete and up-to-date coverage in 10 chapters. It presents information from papers that attempted to associate the virus with diseases in Africa until the first animal experiment; discusses its association with Guillain-Barré syndrome and microcephaly; describes the basic mechanisms for Zika (ZIKV) replication, including important differences between Dengue (DENV), West-Nile virus (WNV), and ZIKV;Table of ContentsPreface ix List of Abbreviations xi 1 The History of ZIKV Discovery 1 1.1 ZIKV Isolation from Monkeys and Mosquitos 1 1.2 ZIKV Infection in Humans 6 1.3 ZIKV Infection Spread to Other Hosts and Regions 7 1.4 Cross‐Paths between ZIKV and Other Flaviviruses 9 References 10 2 ZIKV: From Silent to Epidemic 15 2.1 Outbreak in Yap Island (2007) 15 2.2 Outbreak in French Polynesia (2013) 16 2.3 How Did ZIKV Reach Brazil? 18 2.4 Outbreak in Brazil (2015) 18 2.5 ZIKV Spread through South, Central, and North Americas 20 References 22 3 ZIKV Transmission and Prevention 29 3.1 Modes of Transmission 29 3.2 Prevention 37 References 40 4 Association with Guillain‐Barre Syndrome and Microcephaly 49 4.1 Association with Neurological Disorders 49 References 58 5 ZIKV Animal Models 69 5.1 Animal Models: Embryonated Hen Eggs 69 5.2 Animal Models: Landrace Piglet 69 5.3 Animal Models: Mice 70 5.4 Animal Model: Nonhuman Primate 74 References 78 6 Biology of ZIKV 83 6.1 Structural and Physical Properties of ZIKV Virion 84 6.2 Binding and Entry 87 6.3 Genome Structure 89 6.4 Translation and Proteolytic Processing 91 6.5 Features of the Nonstructural Proteins 92 6.6 RNA Replication 100 6.7 Features of the Structural Proteins 104 6.8 Virus Assembly and Release from Virus‐Infected Cells 107 References 109 7 Zika Virus (ZIKV) Strains and Lineages 131 7.1 East and West African Lineage 131 7.2 Africa vs. Asian/American Lineage 132 References 140 8 ZIKV‐Host Interactions 147 8.1 Systematic Studies to Identify ZIKV Affected Functions and Pathways 147 8.2 Induction and Dysregulation of Innate Immune Responses during ZIKV Infection 150 8.3 Induction of Cell Death and Apoptosis by ZIKV 156 8.4 Induction of Autophagy by ZIKV 160 8.5 Dysregulation of Cell Cycle and Induction of Abnormal Mitosis by ZIKV 163 References 164 9 Inhibitors of ZIKV Replication and Infection 179 9.1 Drugs That Lead to the Destruction of ZIKV Virions 179 9.2 Drugs That Inhibit ZIKV Entry and Endocytosis 180 9.3 Drugs That Target ZIKV NS2B‐NS3 Protease Activity 186 9.4 Drugs That Target ZIKV NS5 RNA‐Dependent RNA Polymerase Activity 191 9.5 Neutralizing Antibodies That Target ZIKV Structural Protein 200 9.6 Drugs That Inhibit ZIKV Infection by Targeting Host Machinery 201 9.7 Drugs That Show Neuroprotective Activity but Do Not Suppress ZIKV Replication: Emricasan 205 9.8 Other Drugs That Inhibit ZIKV Infection Identified from a Screening of FDA‐Approved Drugs 206 References 210 10 Long‐Term Care and Perspectives 229 10.1 Prenatal Care and Diagnosis of Abnormal Fetus Development 229 10.2 Long‐Term Care for Patients Affected by ZIKV 230 10.3 Assistance to Families with Children Affected by ZIKV 230 10.4 Perspectives 231 References 232 Index 237

Read more less

Book SynopsisTHE ESOPHAGUS The Esophagus investigates the anatomy, physiology, and pathology of the esophagus. This sixth edition, revised and updated throughout, also explores the diagnosis and treatment of various esophageal conditions. It includes treatment guidelines approved by the two largest gastroenterology societies, the ACG and AGA, as befits a work co-edited by two former presidents of those organizations. Advancements in diagnostics are presented, as are developments in the surgical and drug therapies.Presented in full colour, and boasting an unrivalled team of editors and contributing authors, The Esophagus Sixth Edition will find a home wherever the anatomy, physiology, and pathology of the esophagus are studied and taught.This book is accompanied by a website containing all the figures from the book in PowerPoint format.www.wiley.com/go/richter/esophagus6ePraise for the Fifth Edition:There is absolutely no doubt that this edition oTable of ContentsContributors Companion Website Preface Section I – Esophageal Symptoms 1 Symptom Overview and Quality of Life John W. Jacobs, Jr. 2 Diagnosis and Treatment of Esophageal Chest Pain Edward C. Oldfield IV, Parth J. Parekh, David A. Johnson 3 Disorders Causing Oropharyngeal Dysphagia Patrick Sanvanson and Reza Shaker 4 The Esophagus: Rumination Syndrome Magnus Halland and David A. Katzka Section 2 – Esophageal Physiology and Testing 5 Functional Anatomy and Physiology of Swallowing and Esophageal Motility Arvind Rengarajan, C. Prakash Gyawali 6 Radiology of the Pharynx and Esophagus Marc S. Levine and Stephen E. Rubesin 7 Special Endoscopic Imaging and Optical Techniques for Evaluating the Esophagus John A. Dumot, John J. Vargo and Arvind Trindade 8 High-Resolution Manometry and Esophageal Pressure Topography Dustin A. Carlson and Peter J. Kahrilas 9 Esophageal Testing Using Multichannel Intraluminal Impedance awaiting Amit Agrawal 10 Ambulatory monitoring for reflux Frank Zerbib, John E. Pandolfino 11 NEW DIAGNOSTIC TESTS FOR GERD Robert T. Kavitt, Michael F. Vaezi 12 Role of Histology and Cytology in Esophageal Diseases Xiuli Liu and John R. Goldblum Section 3 – Motility Disorders 13 Achalasia Guy E. Boeckxstaens, Albert J Bredenoord 14 Non-Achalasia Esophageal Motility Abnormalities Steven Clayton 15 Surgery for Esophageal Motor Disorders – Achalasia/DES/Jackhammer/ EGJOO Brett Parker, Lee L Swanstrom 16 Xxxxxxxxxxxxxxx 17 Esoph Diverticulum 18 Xxxxxxxxxxxxxxx Section 4 – Gastroesophageal Reflux Disease 19 CLINICAL SPECTRUM & DIAGNOSIS OF GERD PHENOTYPES Rena Yadlapati 20 Hiatus Hernia and Gastroesophageal Reflux Disease Wout O. A. Rohof and André J. P. M. Smout 21 Pathophysiology of Gastroesophageal Reflux Disease: Motility Factors Ravinder K. Mittal & Sabine Roman 22 Pathophysiology of Gastroesophageal Reflux Disease: Epithelial Factors Shere Paris, Rhonda F. Souza 23 DUODENOGASTROESOPHAGEAL REFLUX Daniel Sifrim and Roberto Penagini 24 Helicobacter pylori and GERD Kristle Lee Lynch, Gary W. Falk 25 Medical Management of Gastroesophageal Reflux Disease Felice Schnoll-Sussman, Philip O. Katz 26 Refractory Heartburn - Reflux Hypersensitivity and Functional Heartburn Fahmi Shibli, Ronnie Fass 27: Endoscopic Therapies for GERD Kenneth J Chang 28 Behavioral Treatment of Oropharyngeal and Esophageal Disorders Joy E. Gaziano 29 Barrett’s Esophagus Puja Sukhwani Elias, Stuart Jon Spechler 30 Esophageal Strictures Sajiv Sethi, Joel Richter 31 ENT Complaints in GERD Emily C. Ambrose, Kenneth C. Fletcher, C. Gaelyn Garrett 32 Pulmonary Complications of Gastroesophageal Reflux Disease Walter W. Chan 33 Pediatric Gastroesophageal Reflux Disease Rachel Rosen, Samuel Nurko 34 Challenges in the Understanding and Application of Antireflux Surgery for GERD Steven R. DeMeester, Tom R. DeMeester 35 New Surgical Treatments for GERD Reginald Bell 36 Obesity and Gastroesophageal Reflux Disease Hashem B. El-Serag and Aaron P. Thrift Section 5 – Malignant Disease 37 Xxxxxxxxxxxxxxxxxxxxx awaiting 38 Endoscopic Treatment of Esophageal Cancer Prasad G. Iyer, Kenneth K. Wang 39 SURGICAL TREATMENT FOR ESOPHAGEAL CANCER LUIGI BONAVINA, ALBERTO LUPORINI Section 6 – Miscellaneous 40 Eosinophilic Esophagitis Ikuo Hirano, Evan S. Dellon 41 Foreign Bodies Rene D Gomez-Esquivel 42 Medication-Induced Esophageal Injury David A. Katzka 43 Esophagitis in the Immunocompromised Host James P. Callaway and C. Mel Wilcox 44 CAUSTIC INJURIES OF THE ESOPHAGUS Dhyanesh Patel 45 Rupture and Perforation of the Esophagus Phillip S. Ge, Gottumukkala S. Raju 46 CUTANEOUS DISEASES OF THE ESOPHAGUS Michael J. Camilleri 47 Esophageal Disease in Older Patients Kenneth R. DeVault and Sami R. Achem Index

Read more less

Book Synopsis

Read more less

Book SynopsisTextbook of Lifestyle Medicine The Textbook of Lifestyle Medicine provides foundational knowledge essential to students and scientists across various disciplines to better understand this new area of research and practice. Incorporating the latest evidence-based research on the relationships between lifestyle factors and disease, this unique book discusses the practical tools necessary to address growing public health crises such as obesity, cancer, diabetes, and cardiovascular disease using a holistic approach to physical, mental, and spiritual wellness. The book offers comprehensive and up-to-date coverage of how lifestyle medicine professionals can prevent and mitigate Lifestyle Diseases'. Clear and accessible chapters explore modifiable lifestyle factors that positively affect health, nutrition, exercise, sleep, stress control, and social support, and highlight the negative impact of smoking, alcohol abuse, and other unhealthy lifestyles. Topics include sleep physiology, the genetic background and development of noncommunicable diseases (NCDs), the characteristics and principles of healthy lifestyle, the clinical significance of physical activity, and the mechanisms connecting social interaction and health implications. This important resource: Discusses the global burden and risk factors of the modern disease epidemicCovers a variety of nutritional approaches including the Mediterranean Diet and the Dietary Approaches to Stop Hypertension (DASH) dietFeatures in-depth coverage of the Mediterranean Lifestyle, a holistic approach to health and wellnessIncludes a clinical practice section and appendices on preventive medicine and public health tools and recommendationsContains key points, take-home messages, self-assessment questions, color artwork and numerous references, citations, internet links, and further reading suggestions Written by two world experts in this growing field, the Textbook of Lifestyle Medicine is a must-have volume for students and practitioners in nutrition, exercise physiology, psychology, addiction therapy, sleep therapy, as well as physicians, nurses, and other health professionals wanting to expand their knowledge and practice.Trade ReviewThe Textbook of Lifestyle Medicine by the respected biomedical scientists Labros Sidossis and Stephanos N. Kales has been long awaited and is most welcome. New knowledge has confirmed the wisdom of the third branch of Hippocratic Medicine, Dietetics (Diet =way of life) and has revealed the biological basis of ancient promptings for a healthy lifestyle. Lifestyle Medicine is a colossal service of Medicine to Mankind, helping with the prevention and treatment of most of the chronic non-communicable diseases, including anxiety, depression, psychosomatic disorders, obesity, type 2 diabetes mellitus, cardiovascular diseases, autoimmune disorders, osteoporosis, and cancer. The Textbook of Lifestyle Medicine provides a timely great introduction and a systematic guide toward this goal. It represents a major step forward. It is well written, comprehensive, and promoting key aspects of a healthy lifestyle. It will be useful to health care professionals at all stages of their careers, as well as to the public at large. I recommend it enthusiastically and predict many future editions. George P. Chrousos, MD, MACP, MACE, FRCP Professor of Pediatrics and Endocrinology Emeritus, Holder, UNESCO Chair on Adolescent Health Care, Distinguished Investigator Emeritus, NICHD, NIH The Textbook of Lifestyle Medicine by Dr. Kales and Sidossis is an excellent resource for those who want to teach a course focused on the Mediterranean Lifestyle. The key points, take home messages, and self-assessment questions are useful tools for students and teachers. The textbook includes information about the six pillars of lifestyle medicine including exercise, nutrition, sleep, stress reduction, social connections, and avoidance of risky substances. In addition. there are case studies that review patient experiences and successes with a focus on lifestyle as medicine. Elizabeth Pegg Frates, MD President-Elect American College of Lifestyle Medicine The book Lifestyle Medicine by Sidossis and Kales is a “must-have” for anyone who is interested in the role of lifestyle as a determinant of health and wellbeing. The book is wonderfully well written, with a very careful language and aesthetic. One of the most interesting and remarkable aspects is the holistic approach to health and its determinants throughout the book. The authors describe the multi-dimensional nature of lifestyle and explains the importance of each dimension as a determinant of health. The fourth unit is a very valuable tool for professionals who want to apply the principles of the Mediterranean lifestyle to their patients, since each chapter may be used as a guide for a complete assessment of those metabolic diseases and for the promotion of a multidimensional change towards the adoption of a healthier lifestyle. This book is a magnificent work in which Public Health students, medical professionals and public will find the keys to understanding the precepts of lifestyle medicine and the benefits of the Mediterranean lifestyle. Miguel A. Martínez-González, MD, PhD, MPH Adjunct Professor, Nutrition, Harvard TH Chan School of Public Health Professor & Chair of the Department of Preventive Medicine and Public Health, Universidad de Navarra, Pamplona, Spain Steering Committee of PREDIMED As the authors state “even small changes toward healthier lifestyle choices can translate into substantial health benefits”. They then go on to provide the knowledge, evidence, and tools to achieve this aim. The pillars of lifestyle medicine are usefully interwoven throughout the textbook while evidenced key points, practical tips and tools all provide the reader with the ‘ammunition’ to help their patients onto a health trajectory which is relevant to them. A fascinating read and especially so around the traditional Mediterranean diet and lifestyle. Dr Rob Lawson FRCGP, Dip BSLM/IBLM Chair British Society of Lifestyle Medicine President European Lifestyle Medicine Council Chair World Lifestyle Medicine Council Table of ContentsAbout The Authors viii Preface ix Abbreviation List xi Unit I Lifestyle Choices and Human Health 1 Basic Concepts: Health, Wellness, and Lifestyle 3 2 The Lifestyle Disease Epidemic: Global Burden and Risk Factors 7 3 Components of an Unhealthy Lifestyle 14 4 Characteristics and Principles of a Healthy Lifestyle 28 Unit II Healthy Diets 5 Progression from Nutrients to Dietary Patterns 35 6 Popular Dietary Patterns Around the World 40 7 The Mediterranean Diet: A Dietary Pattern That Has Stood the Test of Time 55 Unit III From Mediterranean Diet to Mediterranean Lifestyle 8 The Mediterranean Lifestyle Paradigm 77 9 Physical Activity in the Mediterranean Region 85 10 The Need for Sleep and Its Effect on Health 104 11 Social Life, Spirituality, and Stress Management 115 Unit IV Mediterranean Lifestyle in Clinical Practice 12 Use of the Mediterranean Lifestyle Paradigm in the Prevention and Treatment of the Metabolic Syndrome 125 13 Obesity Case Study 130 14 Type 2 Diabetes Mellitus Case Study 154 15 Hypertension Case Study 169 16 Dyslipidemia Case Study 185 Appendix A Answers to Self-Assessment Questions 202 Appendix B Dietary Models and One-Day Sample Meal Plans 213 Appendix C Food Components of the Mediterranean Diet 231 Appendix D Assessment Tools for the Various Lifestyle Components 242 Glossary 262 Index 265

Read more less

Book SynopsisThe leading guide to vulval diseases The newly updated Fourth Edition of Ridley's The Vulva delivers a practical guide to diagnosing and treating common and uncommon conditions affecting the vulva. The book bridges across the different specialties involved in the study of vulval diseases, offering full colour pictures, a companion website, and a digital companion text. This newest edition provides the most up-to-date guidance on the diagnosis and management of vulval diseases, with extensively revised chapters and brand-new material on paediatric vulval disease, female genital mutilation, and psychological interventions. Finally, a variety of new clinical and histological images are included. The book also provides: A thorough introduction to the basics of vulval disease, including vulval embryology and anatomy, normal vulval microbiology and physiology, and the principles of medical treatmentComprehensive summaries of vulval infections, including herpes simplex, HPV, candidiasis, and ectoparasite infectionsPractical discussions of all vulval dermatoses, including genetic conditions, and signs of associated systemic diseaseIn-depth information on vulvodyniaDiscussion of benign, pre-malignant and malignant lesionsPerfect for dermatology, gynecology, pathology, paediatrics, genito-urinary and urology consultants and trainees, Ridley's The Vulva will also earn a place in the libraries of general practitioners and specialist nurses.Table of ContentsList of Contributors xi Preface xiii Acknowledgements xiv About the Companion Website xv Section 1 The Basics of Vulval Disease 1 1 Vulval Embryology and Developmental Abnormalities 3Fiona M. Lewis 2 The Normal Vulva 19Fiona M. Lewis 3 Vulval Physiology and Changes Through Life 36Fiona M. Lewis 4 Normal Microbiology of the Vulva 42Fiona M. Lewis 5 The Vulval Clinic, History, and Examination 45Fiona M. Lewis 6 Symptoms and Signs in Vulval Disease 51Fiona M. Lewis 7 Investigations in Vulval Disease 56Fiona M. Lewis 8 Topical and Non-Surgical Treatments 63Fiona M. Lewis Section 2 Infection and the Vulva 69 9 Bacterial Vaginosis 71Gulshan Sethi 10 Vulvovaginal Candidiasis 74Gulshan Sethi 11 Syphilis 78Gulshan Sethi 12 Gonorrhoea 83Gulshan Sethi 13 Chlamydial Infection 87Gulshan Sethi 14 Trichomoniasis 91Gulshan Sethi 15 Genital Herpes 94Gulshan Sethi 16 Human Papillomavirus Infections 99Gulshan Sethi 17 Other Sexually Transmitted Infections 105Gulshan Sethi 18 Tropical Infections 110Fiona M. Lewis 19 Non-Sexually Transmitted Infections 117Fiona M. Lewis 20 HIV Infection and Vulval Disease 129Gulshan Sethi Section 3 Inflammatory Dermatoses 131 21 Vulval Psoriasis 133Shireen Velangi 22 Eczema and Allergic Reactions 139Fiona M. Lewis 23 Lichen Sclerosus 147Fiona M. Lewis 24 Lichen Planus 161Fiona M. Lewis 25 Hidradenitis Suppurativa 171Ellie Rashidghamat 26 Immunobullous Disease 180Elisabet Nylander 27 Other Inflammatory Dermatoses 186Fiona M. Lewis Section 4 Other Dermatological Conditions 197 28 Genetic Conditions 199Fiona M. Lewis 29 Disorders of Pigmentation 206Fiona M. Lewis 30 Disorders of Skin Appendages and Hair 213Fiona M. Lewis 31 Drug Reactions and the Vulva 217Fiona M. Lewis 32 Conditions Associated with Systemic Disease 223Fiona M. Lewis 33 Lymphatic Abnormalities and the Vulva 234Kristiana Gordon 34 Vascular Abnormalities and the Vulva 240Fiona M. Lewis Section 5 Vulvodynia 243 35 Vulvodynia: History, Classification, and Terminology 245Nina Bohm-Starke and Ulrika Johannesson 36 Vulvodynia: Pathophysiology and Clinical Features 248Nina Bohm-Starke and Ulrika Johannesson 37 Vulvodynia: Management 260Nina Bohm-Starke and Ulrika Johannesson Section 6 Benign Tumours of the Vulva 269 38 Benign Vulval Tumours 271Zlatko Marusic and Eduardo Calonje 39 Benign Vulval Naevi 287Zlatko Marusic and Eduardo Calonje Section 7 Intraepithelial Lesions 291 40 High-Grade Squamous Intraepithelial Lesions 293Fabrizio Bogliatto and Fiona M. Lewis 41 Differentiated Vulval Epithelial Neoplasia 301Fiona M. Lewis 42 Vulval Paget's Disease 306Michelle van der Linden Section 8 Vulval Cancer 313 43 Vulval Squamous Cell Carcinoma 315Marc van Beurden 44 Malignant Melanoma of the Vulva 327Fiona M. Lewis 45 Other Malignant Vulval Tumours 333Zlatko Marusic and Eduardo Calonje Section 9 Surgical Procedures and Management of Other Conditions 347 46 Female Genital Mutilation 349Refaat Karim 47 Transgender Surgery and the Neovulva 355Fiona M. Lewis Section 10 Psychological Aspects of Vulval Disease 359 48 Psychological Aspects of Vulval Disorders 361Alia Ahmed and Fiona M. Lewis Section 11 Vulval Disease in Children 373 49 Inflammatory Dermatoses of the Vulva in Children 375Fiona M. Lewis 50 Vulval Infection in Children 385Fiona M. Lewis 51 Anatomical Abnormalities in Children 391Fiona M. Lewis 52 Vulval Trauma in Children 396Fiona M. Lewis 53 Vulval Lesions in Children 400Fiona M. Lewis Section 12 Other Topics 403 54 Vulval Trauma 405Fiona M. Lewis 55 Cosmetic Procedures and Complications 412Fiona M. Lewis Glossary of Terms 416 Index 417

Read more less

Book SynopsisAN AUTHORITATIVE SURVEY OF CURRENT RESEARCH INTO CLINICALLY USEFUL CONVENTIONAL AND NONCONVENTIONAL ANTIBIOTIC THERAPEUTICS Pharmaceutically-active antibiotics revolutionized the treatment of infectious diseases, leading to decreased mortality and increased life expectancy. However, recent years have seen an alarming rise in the number and frequency of antibiotic-resistant Superbugs. The Centers for Disease Control and Prevention (CDC) estimates that over two million antibiotic-resistant infections occur in the United States annually, resulting in approximately 23,000 deaths. Despite the danger to public health, a minimal number of new antibiotic drugs are currently in development or in clinical trials by major pharmaceutical companies. To prevent reverting back to the pre-antibiotic erawhen diseases caused by parasites or infections were virtually untreatable and frequently resulted in deathnew and innovative approaches are needed to combat the increasing resistance of pathogenic bacteria to antibiotics. Bacterial Resistance to Antibiotics From Molecules to Manexamines the current state and future direction of research into developing clinically-useful next-generation novel antibiotics. An internationally-recognized team of experts cover topics including glycopeptide antibiotic resistance, anti-tuberculosis agents, anti-virulence therapies, tetracyclines, the molecular and structural determinants of resistance, and more. Presents a multidisciplinary approach for the optimization of novel antibiotics for maximum potency, minimal toxicity, and appropriated degradabilityHighlights critical aspects that may relieve the problematic medical situation of antibiotic resistanceIncludes an overview of the genetic and molecular mechanisms of antibiotic resistanceAddresses contemporary issues of global public health and longevityIncludes full references, author remarks, and color illustrations, graphs, and charts Bacterial Resistance to Antibiotics From Molecules to Manis a valuable source of up-to-date information for medical practitioners, researchers, academics, and professionals in public health, pharmaceuticals, microbiology, and related fields.Table of ContentsList of Contributors vii Preface ix Foreword xiiiAda Yonath 1 Molecular Mechanisms of Antibiotic Resistance – Part I 1Alison J. Baylay, Laura J.V. Piddock, and Mark A. Webber 2 Molecular Mechanisms of Antibiotic Resistance – Part II 27Liam K.R. Sharkey and Alex J. O’Neill 3 Resistance to Glycopeptide Antibiotics 51François Lebreton and Vincent Cattoir 4 Resistance and Tolerance to Aminoglycosides 81Wendy W.K. Mok and Mark P. Brynildsen 5 Tetracyclines: Mode of Action and their Bacterial Mechanisms of Resistance 101Marilyn C. Roberts 6 Fluoroquinolone Resistance 125Karl Drlica, Xilin Zhao, Muhammad Malik, Hiroshi Hiasa, Arkady Mustaev, and Robert Kerns 7 Dihydropteroate Synthase (Sulfonamides) and Dihydrofolate Reductase Inhibitors 163Clemente Capasso and Claudiu T. Supuran 8 Anti‐tuberculosis Agents 173Ying Zhang 9 Multidrug Resistance 201Robert L. Marshall and Vassiliy N. Bavro 10 Anti‐virulence Therapies Through Potentiating ROS in Bacteria 239Kristin J. Adolfsen and Mark P. Brynildsen Index 255

Read more less

Book SynopsisSubstance use and addiction is an increasing problem amongst older people. The identification of this problem is often more difficult in older patients and is frequently missed, particularly in the primary care context and in emergency departments. This book shows how to recognise and treat substance problems in older patients.Table of ContentsContributors xvii Foreword xxi Introduction xxiv List of Abbreviations xxvi Section 1 Legal and ethical aspects of care for older people with substance misuse 1 1 Negotiating capacity and consent in substance misuse 3 Kritika Samsi Introduction 3 Substance abuse and capacity 3 Mental capacity legislation 4 Mental Capacity Act 2005 4 Capacity assessment 5 Capacity and unwise decisions 6 Consent, barriers to decision making and substituted decision making 6 Best interest decisions 8 Independent decision makers 8 Conclusion 9 References 9 2 Elder abuse 11 Jill Manthorpe Introduction 11 Defining elder abuse 11 Main reviews 12 Alcohol and substance misuse risk factors 12 Risk factors among older people 13 The effects of elder abuse 14 Discussion 15 Conclusions and next steps 15 References 16 3 The United States perspective 18 Cynthia M.A. Geppert and Peter J. Taylor The ageing of the baby boomers and its impact on substance abuse 18 Ethical and legal aspects of substance misuse in older adults 19 Confidentiality 19 Informed consent 20 Capacity 21 Coercion 24 Conclusion 25 References 25 4 The European perspective 27 Abdi Sanati and Mohammed Abou-Saleh Introduction 27 Use and possession 28 Crime 28 European Convention of Human Rights 28 Delivering services for the elderly with substance misuse – ethical aspects 29 Research and development 30 Policy making 31 Some differences between Europe and the USA 31 Ethical issues regarding treatment 32 Stigma 32 Underprescribing controlled drugs 32 Summary 33 References 34 5 Clinical medicine and substance misuse: research, assessments and treatment 35 Amit Arora, Andrew O’Neill, Peter Crome and Finbarr C. Martin Introduction 35 Why is clinical medicine important? 36 Identification 37 The health effects of substance abuse 39 Challenges for the future 46 Research 47 Identification tools 47 Training and support 48 Conclusions 49 References 49 Section 2 Epidemiology and demography 57 6 Cigarette smoking among adults aged 45 and older in the United States, 2002–2011 59 Shanta R. Dube and Li-Tzy Wu Introduction 59 Evaluation methodology 61 Results 62 Sociodemographic characteristics of older adults: 2002 versus 2011 62 National trend in current smoking prevalence: 2002–2011 65 Current smoking prevalence by socioeconomic status: 2002 versus 2011 66 Adjusted odds ratios of correlates of current smoking: 2002 versus 2011 66 Discussion 71 Conclusion 72 References 73 7 Epidemiology and demography of alcohol and the older person 75 Stephan Arndt and Susan K. Schultz Introduction 75 Main reviews 76 Epidemiological estimates of prevalence of alcohol use 76 Estimates of alcohol problems based on amount of drinking 76 Importance of threshold selection for defining problem use 80 Estimating problem use from survey samples 80 Summary of epidemiological estimates 81 Specific problematic drinking behaviours: binge drinking 81 Diagnoses of abuse or dependence 83 Older substance abuse treatment populations 84 Special populations of older substance users 85 Demographic correlates of problem use 86 Discussion 87 Conclusions and next steps 87 References 88 8 Epidemiology and demography of illicit drug use and drug use disorders among adults aged 50 and older 91 Shawna L. Carroll Chapman and Li-Tzy Wu Introduction 91 Survey studies 92 Studies of treatment-seeking or clinical patients 101 Health implications 104 Discussion 105 Next steps 106 References 106 9 Epidemiology and demography of nonmedical prescription drug use 109 Jane Carlisle Maxwell Introduction 109 Findings 110 National surveys 110 Emergency department cases 112 Treatment admissions 113 Drug poisoning deaths 114 Discussion 116 Conclusions 118 Acknowledgement 118 References 118 Section 3 Longitudinal studies of ageing and substance abuse 121 10 Ageing and the development of alcohol use and misuse 123 Marja Aartsen Background 123 Results 124 Differences in alcohol use across cohorts 125 Developments in alcohol use within people 126 Gender differences 126 Different trajectories 126 Age and onset of problem drinking 127 Discussion 127 Explanations for age differences in alcohol use 127 Conclusions 128 References 129 11 Progression from substance use to the development of substance use disorders 133 Carla L. Storr and Kerry M. Green Introduction 133 Substance use progression process 134 Risk factors influencing substance use progression 137 Individual factors 137 Substance properties 139 Environmental influences 140 Future direction 141 Conclusions 143 Acknowledgement 144 References 144 12 Psychopharmacology and the consequences of alcohol and drug interactions 149 Vijay A. Ramchandani, Patricia W. Slattum, Ashwin A. Patkar, Li-Tzy Wu, Jonathan C. Lee, Maitreyee Mohanty, Marion Coe and Ting-Kai Li The extent of alcohol and drug misuse among older adults 149 Substance misuse in the general population 149 Substance misuse or addiction in clinical settings 150 Co-morbidities among older substance misusers 151 Psychopharmacology of alcohol and drug misuse in older people 152 Neurocircuitry of abused substances 152 Alcohol–drug interactions in older adults 155 Mechanisms of alcohol–medication interactions 156 Significance of the problem 156 Concurrent use of alcohol and potentially interacting medications 157 Consequences of concurrent use of alcohol and medications 158 Clinical presentation and evaluation of substance use disorders in the elderly 158 Clinical presentations (case vignettes) 159 Medical co-morbidities 161 Screening for substance use disorders 161 Evaluation of substance use disorders 162 Cognitive impairment in the elderly with substance use disorders 163 Safety assessment of the elderly with substance use disorders 164 Medications for individuals with substance use disorders 164 Conclusions 166 References 166 Section 4 Comprehensive geriatric assessment and special needs of older people 171 13 Comprehensive geriatric assessment and the special needs of older people 173 Dan Wilson, Stephen Jackson, Ilana B. Crome, Rahul (Tony) Rao and Peter Crome Background 173 Assessment 175 Setting 176 Barriers to assessment 176 High-risk groups 177 Presenting problems 177 Collateral information 178 General principles of assessment 179 Screening 182 Psychiatric assessment 183 Case presentations 184 Driving and substance misuse 184 Older women and alcohol misuse 184 Polysubstance misuse 185 The frequent attender 185 Alcohol and cognitive impairment 186 Pain and substance misuse 187 Discussion 187 Conclusion 187 References 188 Section 5 Screening and intervention in health care settings 193 14 Screening and brief intervention in the psychiatric setting 195 M. Shafi Siddiqui and Michael Fleming Overview 195 Screening and assessment for alcohol use disorders 197 Single question screen for an alcohol use disorder 197 Quantity and frequency questions 198 Proxy questions such as CAGE 198 Symptoms of abuse or dependence 199 Alcohol biomarkers 199 Illicit drugs 202 Rationale for screening older adults for marijuana, cocaine and other illicit drugs 202 Screening for illegal drugs in the psychiatric setting 202 Recommended screening questions to detect drug use 202 Screening for drug abuse/dependence 203 Screening for illicit drug use with toxicology screening 203 Prescription drug abuse 204 Rationale for screening older adults 204 Screening for prescription drug abuse 205 Brief intervention for alcohol, prescription drug abuse and illegal drug use 206 Summary 208 References 209 15 Tobacco use cessation 212 Daniel J. Pilowsky and Li-Tzy Wu Introduction 212 Smoking cessation interventions among older adults 214 Multimodal interventions 214 Medication-based interventions 216 Counselling and behavioural interventions 217 Physician-delivered interventions 217 Other interventions 218 Conclusions 218 References 219 Section 6 Use of substance abuse treatment services among older adults 223 16 Epidemiology of use of treatment services for substance use problems 225 Shawna L. Carroll Chapman and Li-Tzy Wu Introduction 225 Tobacco cessation service use and characteristics 225 Alcohol treatment use and characteristics 230 Trend in substance abuse treatment admissions 238 Drug abuse treatment use and outcomes 243 Substance abuse treatment in general health care settings 245 Discussion and conclusion 246 References 247 17 Implications for primary care 249 Devoshree Chatterjee and Steve Iliffe Background 249 Implications for primary care 249 Different populations at risk 250 Screening in primary care 251 Scale of benefit 252 Co-morbidities and social context 252 Conclusions 253 References 253 18 Addiction liaison services 255 Roger Bloor and Derrett Watts Introduction 255 Organizing an addiction liaison service to a general hospital 256 Case vignette 1 256 Addiction liaison services for older adults 257 Essential elements of liaison service provision for older adults 258 Screening for alcohol problems in older adults 259 Screening for drug use problems 260 Case vignette 2 260 Summary 261 References 262 19 Current healthcare models and clinical practices 265 Rahul (Tony) Rao, Ilana B. Crome, Peter Crome and Finbarr C. Martin Introduction 265 An ageing population 265 Service development and provision 266 Integrated care and workforce development 267 Conclusions and recommendations 269 References 269 Section 7 Age-specific treatment interventions and outcomes 271 20 Pharmacological and integrated treatments in older adults with substance use disorders 273 Paolo Mannelli, Li-Tzy Wu and Kathleen T. Brady Introduction 273 Tobacco 274 Alcohol 275 Opioids 277 Benzodiazepines 278 Other substances of abuse 280 Stimulants 280 Cannabis 281 Integrated treatments 281 Conclusion and future directions 284 References 285 21 The assessment and prevention of potentially inappropriate prescribing 295 Denis O’Mahony Introduction 295 Inappropriate psychotropic use in elderly patients 296 Implicit IP criteria 297 Explicit IP criteria 298 Applying STOPP/START criteria as an intervention 299 Other methods of detection and prevention of IP in older people 307 Comprehensive Geriatric Assessment (CGA) 307 Pharmacist review and intervention 308 Prescriber education, audit and feedback 308 Computerized provider order entry with clinical decision support 309 Conclusions 309 References 310 22 Age-sensitive psychosocial treatment for older adults with substance abuse 314 Kathleen Schutte, Sonne Lemke, Rudolf H. Moos and Penny L. Brennan Introduction 314 Seven characteristics of age-sensitive treatment 316 1 – Supportive and nonconfrontational 316 2 – Flexible 316 3 – Sensitive to gender differences 317 4 – Sensitive to cultural differences 317 5 – Focus on client functioning 318 6 – Holistic 319 7 – Focus on coping and social skills 319 Six components of age-sensitive psychosocial treatment 320 1 – Biopsychosocial assessment 320 2 – Treatment planning 321 3 – Attention to co-occurring conditions 322 4 – Referrals and care coordination 325 5 – Empirically-supported psychosocial interventions 325 6 – Adjuncts to psychosocial interventions 328 Age-segregated or mixed-age treatment 329 Future directions 330 Acknowledgements 331 References 332 23 Integrated treatment models for co-morbid disorders 340 Rahul (Tony) Rao Introduction 340 Methodological approach to examining SMCD in older people 341 A. Current systems of care for substance misuse and mental disorders 341 B. Service implications 342 C. Principles underlying integrated treatment models for SMCD in older people 342 D. Developing integrated treatment models for older people with substance misuse and co-morbid psychiatric disorders 344 E. Research evidence for integrated treatment models 346 Future direction and challenges 347 References 347 Section 8 Policy: proposals for development 351 24 Proposals for policy development: drugs 353 Susanne MacGregor Introduction 353 Recognition of a need or problem and arguments made to justify the development of policy 354 Policy options 356 Policy design and implementation 359 Conclusion 360 References 360 25 Proposals for alcohol-related policy development United States 364 Ralph Hingson and Ting-Kai Li Recommended low-risk alcohol consumption levels 364 Traffic crash risks among the elderly 365 Driving policy questions 365 Factors to consider when contemplating legal policies 365 Summary and conclusions 369 References 370 26 Proposals for policy development: tobacco 372 Michael Givel Introduction 372 Past and present approaches to reduce tobacco consumption 372 Phase three anti-tobacco efforts 373 Legal approach 373 Regulatory and tobacco tax approaches 374 Anti-tobacco counter-marketing campaigns 376 Recent anti-tobacco proposals 376 Product modification and ‘safer’ cigarettes 376 Harm reduction 377 Cigarette neo-prohibitionism 377 Smoke-free movies 377 Policy proposals to further reduce tobacco prevalence 378 References 378 27 Recommendations 383 Ilana B. Crome, Peter Crome, Rahul (Tony) Rao and Li-Tzy Wu Background 383 Epidemiology 384 Clinical presentations 384 Education and training 385 Who gets treatment – treatment interventions 386 Concluding remarks 386 Index 388

Read more less

Book Synopsis

Read more less

Book SynopsisTable of ContentsPrefaceSECTION 1 SCREENING 1. Behavioral Health and Substance Use Disorders 2. Cardiovascular Disorders 3. Disorders of the Skin, Breast, and Musculoskeletal System 4. Endocrine and Metabolic Disorders 5. Gastrointestinal Disorders 6. Genitourinary Disorders 7. Infectious Diseases 8. Pulmonary Disorders 9. Renal Disorders 10. Special Population: Children and Adolescents 11. Special Population: Newborns and Infants 12. Special Population: Older Adults 13. Special Population: Pregnant WomenSECTION 2 PREVENTION 14. Cardiovascular Disorders 15. Disorders of the Skin, Breast, and Musculoskeletal System 16. Endocrine and Metabolic Disorders 17. Gastrointestinal Disorders 18. Genitourinary Disorders 19. Infectious Diseases 20. Renal Disorders 21. Special Population: Children and Adolescents 22. Special Population: Newborns and Infants 23. Special Population: Older Adults 24. Special Population: Pregnant WomenSECTION 3 MANAGEMENT 25. Behavioral Health Disorders 26. Cardiovascular Disorders 27. Care of the Older Adult 28. Disorders of the Head, Eye, Ear, Nose, and Throat 29. Disorders of the Skin, Breast, and Musculoskeletal System 30. Endocrine and Metabolic Disorders 31. Gastrointestinal Disorders 32. Genitourinary Disorders 33. Hematologic Disorders 34. Infectious Diseases 35. Neurologic Disorders 36. Prenatal and Obstetric Care 37. Pulmonary Disorders 38. Renal Disorders 39. AppendicesIndex

Read more less

Book Synopsis

Read more less

Book Synopsis

Read more less

Book Synopsis

Read more less

Book SynopsisJones & Bartlett Learning's Pocket Guide for Medical Assisting provides the essential information you need to make the transition from the classroom to the clinic as smooth and as stress-free as possible. The streamlined, quick-reference format allows you to easily find key information to carry out clinical, administrative, and laboratory duties. It keeps all the essential information at hand and organized for easy review and is the ideal procedure manual every medical assistant needs for the practice setting.

Read more less

Book Synopsis

Read more less

Book SynopsisThis book is the definitive reference on two of the most exciting areas of cardiovascular research - myocardial regeneration and stem cell therapy - for the treatment of disease.Trade Review“This book brings together the world’s foremost experts in the areas of stem cell biology and their role in cardiovascular patho-physiology. [A] highly enjoyable review of the current knowledge … and it succeeds in covering the current knowledge authoritatively. An essential book for clinicians and fundamental scientists working in this area.” (Cardiology News, December 2008) “The authors have played a major role in developing this new topic…and it is of high relevance in ongoing clinical trials and future treatment perspectives.” (Journal of the American Medical Association) Table of ContentsContributors. Preface. Introduction. Annarosa Leri, Piero Anversa, William Frishman. Part I Stem Cell Biology. 1 Homing of Stem Cells and Tissue Injury. Ayelet Dar, Orit Kollet, Tsvee Lapidot. 2 Adult Stem Cell Plasticity: Lineage potential on a Continuum. Peter J. Quesenberry, Gerald Colvin, Mehrdad Abedi. 3 Embryonic Stem Cells and Cardiogenesis. Timothy J. Kamp, Gary E. Lyons. 4 Mesenchymal Stem Cell-Derived Cardiomyogenic Cells. Keiichi Fukuda, Jun Fujita, Daihiko Hakuno, Shinji Makino. 5 Bone Marrow Cells and Vascular Growth. Takayuki Asahara. 6 Progenitor Cells and Vascular Repair. Kaushik Mandal, Marjan Jahangiri, Qingbo Xu. Part II Cardiac Progenitor Cells in the Adult Heart. 7 Cardiac Side Population Cells: Phenotype and Functional Significance. Ronglih Liao, Frederic Mouquet, Otmar Pfister. 8 Phenotype and Function of c-kit Positive-Derived Amplifying Myocytes. Rachel Wilson, Xiongwen Chen, Hajime Kubo, Remus Berretta, Steven Houser. 9 Cardiac Stem Cells and their Niches. Annarosa Leri, Alessandro Boni, Robert Siggins, Angelo Nascimbene, Toru Hosoda. 10 Activation of the Local Regenerative System of the Heart. Antonia Germani, Federica Limana, Maurizio C. Capogrossi. Part III Progenitor Cells and the Diseased Heart. 11 Embryonic Stem Cells and Myocardial Regeneration. Ahmad Y. Sheikh, Phillip C. Yang, Joseph C. Wu, Robert C. Robbins. 12 Bone Marrow-Derived Cells in Myocardial Repair and Regeneration. Raj Kishore, Douglas W. Losordo. 13 Endothelial Progenitor Cells And The Infarcted Heart. Stefanie Dimmeler, Masamichi Koyanagi, Carmen Urbich, Andreas M. Zeiher. 14 Cytokines and Heart Remodeling. Issei Komuro, Hiroyuki Takano. 15 IGF-1, Muscle Progenitors and Heart Failure. Nadia Rosenthal, Nadine Winn, Maria Paola Santini. Part IV Cardiac Progenitor Cells and Heart Failure. 16 Cardiac Stem Cells and the Diabetic Cardiomyopathy. Jan Kajstura, Nicole LeCapitaine, Maria Loredo, Marco Giorgio, Thomas S. Mitchell, Susanna Valentini, Francesco Rotatori, Pier Giuseppe Pelicci. 17 Stem Cells and Cardiac Aging. Roberto Bolli, Piero Anversa. 18 Bioengineered Scaffolds: Myocytes, Endothelial Cells and Cardiac Repair. Vincent F.M. Segers, Richard T. Lee. 19 Gene Therapy and Cellular Therapy in Cardiac Repair. Mark A. Sussman. 20 Cardiac Stem Cells and the Failing Heart. Piero Anversa, Konrad Urbanek, Claudia Bearzi, Antonella De Angelis, Marcello Rota. 21 Myocardial Infarction: Risks and Hope. Marc A. Pfeffer. Part V Future Directions. 22 Conclusions – Future Directions. Piero Anversa, Edmund H. Sonnenblick, William Frishman. Index

Read more less

Book SynopsisThis new textbook has an international authorship and is a practical, up-to-date resource for clinicians responsible for the care of children with oncologic and malignant hematologic disease. Itis specifically designed for practicing oncologists and hematologists, pediatricians with an interest in childhood cancer and trainees seeking a systematic approach to these disorders. This new textbook has an emphasis on the visual presentation and ease of reading of contemporary and comprehensive information for children's cancers and contains detailed tables, fact boxes and illustrations. The textbook begins with an introduction to the general principles of the scientific foundation and treatment of childhood cancers and hematological malignancies. Separate sectionsare then devoted to descriptions of central nervous system tumors, hematological malignancies and solid tumors of childhood which encompass epidemiology, cellular and molecular biology, cancer genetics, immunology, pharmacologTrade Review“It is compact, concise, and easy to read and understand, and certainly a useful addition to the field.” (Doody's, 3 August 2012) "However, overall, this is a useful book, probably most useful for paediatricians who may be providing shared care for paediatric oncology patients, junior doctors on haematology/oncolgy ward." (The Bulletin of the Royal College of Pathologists, 1 July 2011)Table of ContentsContributors. 1 Introduction (Edward J. Estlin, Richard J. Gilbertson and Robert F. Wynn). Part I Central Nervous System Tumors of Childhood. 2 Low- and High-Grade Glioma (Ian F. Pollack). 3 Ependymoma (Thomas E. Merchant and Richard J. Gilbertson). 4 Embryonal Tumors (Amar Gajjar and Steven C. Clifford). 5 Pediatric Spinal Cord Tumors (Annie Huang, Ute Bartels and Eric Bouffet). 6 Pediatric Craniopharyngioma, Mixed Glioneuronal Tumors, and Atypical Teratoid/Rhabdoid Tumor (Adrienne Weeks and Michael D. Taylor). Part II Hematological Disorders. 7 Acute Lymphoblastic Leukemia (Robert F. Wynn). 8 Acute Myeloid Leukemia and Myelodysplastic Disorders (David K.H. Webb). 9 Non-Hodgkin’s Lymphoma (Angelo Rosolen and Lara Mussolin). 10 Hodgkin's Lymphoma (Wolfgang Dörffel and Dieter Körholz). 11 Histiocytic Disorders (Sheila Weitzman and R. Maarten Egeler). Part III Solid Tumors of Childhood. 12 Neuroblastoma (Sucheta J. Vaidya and Andrew D. J. Pearson). 13 Renal Tumors (Edward J. Estlin and Norbert Graf). 14 Soft Tissue Sarcoma (Gianni Bisogno and John Anderson). 15 Bone Tumors (Richard Gorlick, Martha Perisoglou and Jeremy Whelan). 16 Hepatic Tumors (Penelope Brock, Derek J. Roebuck and Jack Plaschkes). 17 Germ Cell Tumors (James Nicholson and Roger Palmer). 18 Retinoblastoma (Edward J. Estlin, François Doz and Michael Dyer). 19 Rare Tumors (Bernadette Brennan and Charles Stiller). Part IV Supportive Care, Long-Term Issues, and Palliative Care. 20 Supportive Care: Physical Consequences of Cancer and its Therapies (Bob Phillips and Roderick Skinner). 21 Psychosocial Needs of Children with Cancer and Their Families (Ged Lalor and Louise Talbot). 22 Late Effects in Relation to Childhood Cancer (Louise Talbot and Helen Spoudeas). 23 Palliative Care (Lynda Brook). 24 Clinical Trials Involving Children with Cancer – Organizational and Ethical Issues (Sue Ablett and Edward J. Estlin). Index. Colour plate.

Read more less

Book SynopsisCovering all the major tropical diseases that present a health risk to travelers, this book is an invaluable resource for all practitioners who encounter the post travel patient. With emphasis on clinical signs, diagnosis and treatment, it is the first book to summarize the knowledge of post travel presentations in the otherwise non-immune and non-endemic population and will aid clinicians to evaluate travelers' symptoms. The book is divided into three parts. The first is an overview of key aspects of travel medicine; the second contains a detailed discussion of multiple viral, bacterial and parasitic infections. The third part provides a syndromic approach to patients with common travel complaints such as diarrhea, fever and respiratory infections. It also includes useful appendices with lists of anti-parasitic drugs and available diagnostic tests.Trade Review"This book contributes much information to assist in understanding diseases encountered by travelers. It is a valuable reference on tropical and travel medicine and is especially important to clinicians managing ill travelers." (Emerging Infectious Diseases, November 2009)Table of ContentsPreface. Part I: Tropical Diseases in Travelers: General Aspects:. 1. Introduction: Eli Schwartz. 2. The Art of Travel Medicine a Century Ago: Eli Schwartz. 3. Epidemiology of Post-Travel Illness: Pamela Rendi-Wagner and Eli Schwartz. 4. Travelers as Sentinels for Disease Occurrence in Destination Countries: David O. Freedman and Eli Schwartz. 5. VFR (Visiting Friends and Relatives) Travelers: Phyllis E. Kozarsky and Jay S. Keystone. 6. Post-Tropical Screening: Joanna Herman and Peter L. Chiodini. Part II: Specific Infections:. 7. Dengue Fever: Eli Schwartz. 8. West Nile Fever: Michal Chowers. 9. Japanese Encephalitis in Travelers: John Simon. 10. Yellow Fever, and Yellow Fever Vaccine–Associated Disease: Elizabeth D. Barnett. 11. Chikungunya: An Emerging Disease in Travelers: Fabrice Simon, Elodie Vivier and Philippe Parola. 12. Ross River Virus: Joseph Torresi. 13. Viral Hemorrhagic Fevers: Annelies Wilder-Smith. 14: Rabies and the Traveler: Henry Wilde and Thiravat Hemachudha. 15: Hepatitis A and E: The Enterically Transmitted Hepatitis: Nancy Piper Jenks and Eli Schwartz. 16. Typhoid and Paratyphoid Fever: Eli Schwartz. 17. Bacterial Diarrhea: Herbert L. DuPont. 18. Rickettsial Diseases: Mogens Jensenius and Philippe Parola. 19: Relapsing Fever: Gil Sidi and Eli Schwartz. 20. Leptospirosis: Eyal Leshem and Eli Schwartz. 21. Malaria in Travelers: Epidemiology, Clinical Aspects and Treatment: Eli Schwartz. 22. Malaria Diagnosis in Travelers: R. Scott Miller. 23. Malaria–Prevention: Eli Schwartz. 24. Schistosomiasis: Eli Schwartz. 25. Filarial Infections: Thomas B. Nutman. 26. Human Trypanosomiasis: African and American Tryponasomiasis (Chagas): Johannes A. Blum. 27. Cystic Echinococcosis: Enrico Brunetti. 28. Neurocysticercosis: Eli Schwartz. 29. Histoplasmosis and and Other Endemic Fungal Infections: Michael J. Segel and Eli Schwartz. 30. Intestinal Protozoa: Giardia, Amebiasis, Cyclospora, Blastocsystis Hominis, Dientamoeba Fragilis and Cryptosporidium Parvum: Karin Leder. 31. Intestinal Helminths: Strongyloides stercoralis, Ascaris Lumbricoides, Hookworm, Trichuris Trichiuria, Enterobius Vermicularis, Trichinella, Intestinal Tapeworms and Liver Flukes: Karin Leder. 32. Leishmaniasis: Eli Schwartz. 33. Ectoparasites: Myiasis, Tungiasis, Scabies: Eli Schwartz and Eric Caumes. 34. Helminthic Skin Diseases in Travelers: Eric Caumes. 35. Delusional Parasitosis: Eli Schwartz, Jay Keystone and Henry Abramovitch. Part III: Syndromic Approach: . 36. An Approach to the Patient with Post-travel Diarrhea: Eli Schwartz and Bradley A. Connor. 37. Approach to the Patient with Fever: Eli Schwartz. 38. Approach to Returning Travelers with Skin Lesions: Eric Caumes. 39. Approach to Travel-Related Eosinophilia: Eyal Meltzer and Eli Schwartz. 40. Approach to Patients with Protracted Rheumatological Manifestations: Eli Schwartz and Michael Ehrenfeld. 41. Travel Related Respiratory Infections: Eyal Meltzer and Eli Schwartz. 42: Neurological Signs and Symptoms in Travelers: Einar P. Wilder-Smith and Annelies Wilder-Smith. 43. Closing Remarks: Eli Schwartz. Appendixes. A. Useful Anti-Parasitic Drugs. B. Diagnostic Tests Available for Tropical Diseases. Index

Read more less